PRELIMINARY PROGRAM
Updated 9/8/2016. Information subject to change.
THURSDAY, OCTOBER 20, 2016
8:30 a.m. - 5:00 p.m.
New Assessor Training
Event Description: The session is designed for current AABB assessor and all who
complete the training will receive a Certificate of Completion. An approved assessor
application must be on file before you can register for this course. If you are interested
in becoming an AABB assessor, please email accreditation@aabb.org
10:00 a.m. – 3:00 p.m.
ASQ Certification Exam
1:30 p.m. - 5:00 p.m.
(HEMO) Introduction to Hemovigilance Workshop
Director: Barbee Whitaker, PhD
Moderator: Jeannie Callum, MD, BA, FRCPC, CTBS
Speaker: Salvadore Rico; C. Palani Palaniappan; Manette Niu, MD; Misha
Baker, MPH; Jeannie Callum, MD, BA, FRCPC, CTBS; Barbee Whitaker, PhD
Intended Audience: Physicians, Scientists, Technologists, Nurses,
Managers/Supervisors
Teaching level: Basic to Intermediate
Objectives:




Learn how Hemovigilance is practiced in the US and how hospitals can
participate.
Follow the practical steps to enter records into the CDC NHSN Hemovigilance
Module.
Discuss what has been learned from hemovigilance programs globally and
how these lessons can be implemented locally to improve transfusion safety
patient outcomes in your hospital.
Explore the use of hemovigilance data in the development and
implementation of innovations in blood safety and how these hemovigilance
can be used to enhance your quality system.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 1
Event Description: This workshop provides an opportunity for attendees to obtain a
comprehensive view of hemovigilance in the US, including regulatory requirements from
FDA, the voluntary CDC National Healthcare Safety Network Hemovigilance Module
and the AABB Center for Patient Safety. Learn what it takes to participate and how you
and your hospital can benefit from participation.
FRIDAY, OCTOBER 21, 2016
8:00 a.m. - 5:30 p.m.
(1002) Patient Blood Management Workshop
Director: Barbara Bryant, MD, MT(ASCP)SBB
Speaker: Jonathan Waters, MD; Mark Friedman, DO; Courtney McClellan; John Hess,
MD, MPH, FACP, FAAAS; Mark Yazer, MD; Michael Auerbach
Intended Audience: Physicians, Technologists, Nurses
Teaching level: Intermediate to Advanced
Event Description: Patient Blood Management (PBM) plays a vital role in health care
decisions and offers a solution to a number of current healthcare challenges. Come
learn how a successful approach to PBM can improve patient care and how PBM plays
an essential role in bringing optimal care across different disciplines and service lines.
This workshop will help you understand the role of PBM today as the new standard of
care and how it will continue to evolve and improve patient care in the future.
8:30 a.m. - 5:00 p.m.
(99) Assessor Continuing Education Program
Director: Anne Chenoweth, MBA, MT(ASCP)CM, CQA(ASQ)
Assessor Speaker: Eva Quinley, MS, MT(ASCP)SBB, CQA(ASQ); Meredith Reyes,
MD; Kelley Capocelli, MD; Anne Chenoweth, MBA, MT(ASCP)CM, CQA(ASQ);
Maureen Beaton, MT(ASCP)BB, CQA(ASQ); Chelsea Nieuwenkamp, MLS(ASCP)
Intended Audience: Physicians, Technologists, Nurses, Managers/Supervisors,
Perfusionists
Objectives:
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 2




Recognize assessment road blocks and determine how to successfully overcome
them.
Gain knowledge and understanding of the new Accreditation database and its
use.
List ways and tactics to effectively manage teams, handle conflict and provide
superior customer service.
Describe how recent changes in the blood bank community affect the assessor’s
role in the accreditation process.
Event Description: The Assessor Continuing Education program session is designed
as a continuing education course for current AABB assessors. This program with
showcase and recognize barriers and how to successfully conquer them. The learner
will also obtain new information on Accreditation and improved ways to engage and
lead their counter parts in the same efforts. An approved assessor application must be
obtained prior to course register. If you are interested in becoming an AABB assessor,
please email accreditation@aabb.org
Event Level: Intermediate
5:30 p.m. - 7:00 p.m.
Cellular Therapy Networking Reception
Patient Blood Management Workshop Showcase Reception
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 3
SATURDAY, OCTOBER 22, 2016
8:30 am – 10:00 am
Opening General Session
10:30 a.m. - 12:00 p.m.
(9101-S-CT) Antigen-Specific T Cells: Progress and Challenges
Director/Moderator: Yvette Tanhehco, PhD, MD, MS
Speaker: Pawel Muranski, MD; David Stroncek, MD
Intended Audience: Physicians, Scientists, Technologists
Teaching level: Basic to Intermediate
Objectives:



Discuss the efficacy and limitations of virus and fungus-specific T cell
therapy for hematopoietic stem cell transplant recipients.
Discuss the current state of antigen-specific T cell therapy for non-viral
cancers.
Discuss the process and regulatory requirements for manufacturing
antigen-specific T cells.
Event Description: Adoptive immunotherapy with antigen-specific T cells has
been gaining traction over the past few years because of many potential benefits
as a treatment for virus-associated diseases and malignancies. Viral and fungal
infections are a major cause of morbidity and mortality in immunocompromised
patients such as hematopoietic stem cell transplant recipients. Pharmacologic
treatments are available for patients with some types of viral infections, but these
often have limited efficacy and significant adverse effects. Since antigen-specific
T cells have shown significant activity against virus-associated tumors, this
strategy is also being explored for the treatment of non-viral cancers. This
session will discuss the progress and challenges associated with antigen-specific
T cell therapy of virus-associated diseases and malignancies.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 4
(9102-S) Mechanisms of Hemolysis-Driven Vascular and Immune Reactivity in
Hemolytic Diseases
Director/Moderator: Karina Yazdanbakhsh, PhD
Speaker: Gregory Vercellotti, MD; Mark Gladwin, MD; Karina Yazdanbakhsh,
PhD
Intended Audience: Physicians, Scientists
Teaching level: Intermediate to Advanced
Objectives:



To discuss recent insights into mechanisms hemolysis-driven vascular
dysfunction in patients with sickle cell disease and the effect of acute and
chronic transfusions.
To describe molecular pathways of hemolysis-associated inflammation.
To discuss innate and adaptive response to hemolysis in transfused
patients with sickle cell disease and impact on alloimmunization.
Event Description: Free hemoglobin and its reactive iron protoporphyrin group
(heme) released during intravascular hemolysis has deleterious effects on the
vasculature in part through oxidative damage and depletion of nitric oxide.
Patients with sickle cell disease (SCD) experience chronic intravascular
hemolysis, and the vascular effects of chronic or intermittent exposure to free
hemolglobin/heme may be responsible for many of the SCD complications
pulmonary hypertension and vaso-occlusive crisis. Recent studies in some
models suggest that free heme can also trigger activation of Toll-like receptors
(TLRs) and downstream inflammatory signaling, suggesting that ongoing
hemolysis can drive immune dysregulation. In this session, we will discuss recent
developments in our understanding of how hemolysis affects pulmonary
endothelial remodeling in SCD and the effects of acute and chronic transfusions
on endothelial function. We will describe the molecular pathways that drive
hemolysis-driven inflammation and potential therapeutic strategies that can
reverse them. In addition, we will discuss the impact of hemolysis on the innate
immune cells including monocytes and dendritic cells in patients with SCD and
how this has implications for adaptive immune response to transfusions and
alloimmunization.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 5
(9103-S) TTD I: Emerging Infectious Diseases and Other Blood Screening Issues
Director/Moderator: Susan Stramer, PhD
Speaker: Susan Stramer, PhD; Louis Katz, MD; Roger Dodd, PhD
Intended Audience: Physicians, Scientists, Technologists, Nurses
Teaching level: Intermediate to Advanced
Objectives:



Provide background on emerging arboviral infections of concern to
recipient safety.
Provide an update to the status of Babesia microti interventions with
emphasis on evolving policy.
Can we/should we rethink current testing measures?
Event Description: This session will provide an update regarding emerging
infectious disease agents of diverse types, clinical presentations and geographic
distributions for which an intervention is lacking or not required. For some agents,
transfusion transmission may not yet be described or the agent's prevalence and
associated disease burden is unknown or at a clinically tolerable level. The
results of what is known about a select group of agents will be described as well
as the results of studies investigating potential interventions. New FDA
regulations provide a structure for testing for relevant transfusion transmissible
infections (RTTIs). An overview of the regulation focusing on these RTTIs will be
provided as well as thoughts on the question "Can we/should we rethink current
testing measures?"
(9104-TC) New Approaches to Treat Post Transplant and Surgical
Thrombocytopenias
Director/Moderator: Pampee Young, MD, PhD
Speaker: Terry Gernsheimer, MD; Eric Gehrie, MD; David Kuter, MD, DPhil,
FRCPath
Intended Audience: Physicians, Scientists, Technologists, Nurses
Teaching level: Intermediate to Advanced
Objectives:



Review thrombopoiesis and receptors which regulate this process.
Clinical findings in the use of thrombopoietin receptor agonists in immune
thrombocytopenia (ITP).
Recent progress and findings in application of TPO agonists in surgical
thrombocytopenia.
Event Description: Thrombopoietin (TPO) regulates thrombopoiesis through
activation of TPO receptors on the megakaryocyte cell surface, resulting in
increased platelet production. The TPO receptor agonists are novel treatments
for patients with chronic ITP aimed at increasing platelet production through
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 6
interactions with the TPO receptor on megakaryocytes. Two TPO receptor
agonists, romiplostim and eltrombopag, have received regulatory approval. More
recently TPO receptor agonists have been used to treat surgical
thrombocytopenia. We will discuss clinical data on the efficacy, safety, costeffectiveness, and impact on health-related quality of life of TPO receptor
agonists in these applications.
(9105-TC) Evaluating Antibodies for Clinical Significance, One Blood Group
System at a Time
Director/Moderator: E. Ann Steiner, MT(ASCP)SBB
Check back for faculty and a detailed description.
(9106-TC-HEM) Hemovigilance 101: How to Get Started and Why?
Director/Moderator: Barbee Whitaker, PhD
Speaker: Barbee Whitaker, PhD; Kathryn Haass, MPH, CPH, MT(AAB),
BB(ASCP)M; Melanie Jorgenson, RN, BSN
Intended Audience: Physicians, Scientists, Technologists, Nurses,
Managers/Supervisors
Teaching level: Basic to Intermediate
Objectives:



Increase awareness of hemovigilance and its use in the practice of
transfusion medicine.
Provide helpful instruction and tools for hospitals at various levels of
hemovigilance.
Describe how hemovigilance benchmarking data can be used to improve
performance and utilization.
Event Description: This session is designed to provide an introduction to
hemovigilance. The history of hemovigilance, the important lessons learned, and
the ongoing benefits of participation in hemovigilance programs will be
discussed. Instructions for how to get started using hemovigilance definitions,
how to enroll in the CDC NHSN Hemovigilance Module, how to participate with
the AABB Center for Patient Safety will be explained. Lessons from a LEAN six
sigma case study where the adverse event process from patient to blood center
to reporting was streamlined will be highlighted.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 7
(9107-TC) Granulocyte Transfusion: Is it Effective? And is it Safe?
Director/Moderator: Shiu-Ki Hui, MD
Speaker: Fernando Martinez, M.D.; Brian Castillo, MD; Shiu-Ki Hui, MD
Intended Audience: Physicians, Scientists, Technologists, Nurses
Teaching level: Intermediate to Advanced
Objectives:



Describe the current published literatures on granulocyte transfusion in
both adult and pediatric settings.
Describe the component that is needed for an effective granulocyte
transfusion.
List the most common complications from granulocyte transfusion.
Event Description: Granulocyte transfusion although has been around for
decades, it's effectiveness continues to be a subject of debate. The RING trail
has recently shred some much needed light to the subject of granulocytes.
However, in regard to pediatrics its effectiveness remained unaddressed. There
is also a lack of dedicated data on safety of granulocytes transfusion especially in
regard to risk of CMV infection as the product cannot be leukoreduced. This
session will present both published and local data on granulocytes transfusion in
pediatrics in regard to both effectiveness and safety. In addition, this session will
discuss the published data and local data on granulocytes transfusion in adults
and how one large cancer focus hospital integrates these information into its
current practice.
(9108-QE) Moving Beyond Root Cause Error Analysis to Future Error Prevention
Director/Moderator: Galen Kline, BS, CLSSBB
Speaker: Matthew Audette; Beth Hughes, MT (ASCP); Galen Kline, BS,
CLSSBB
Intended Audience: Managers/Supervisors
Teaching level: Intermediate
Objectives:



Discuss the concept of institutional learning and the benefits of designing
work so that they are efficient and safe rather than spending more time
dealing with the aftermath.
Discuss real life instances in the Blood Center and Transfusion Service
realm that led to reduced problems in the future from learned lessons in
the past.
Review tools that can be utilized to solve problems that haven't occurred
yet.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 8
Event Description: The world continues to change and move at a rapid pace.
With change comes more challenges to face from errors to inefficient process.
Hours are spent trying to understand these issues and fix them after they
happen. But what if we could do more to predict what will happen in the future
and change the process beforehand. This session will discuss tools and
practices blood centers and hospital based transfusion services use, such as
process design and institutional learning and knowledge from past performance,
to better align to a change and reduce the likelihood of failures.
(9109-QE-PBM) Tools and Tricks for Your PBM Program Toolkit (PBM)
Director: Nanci Fredrich, RN, BSN, MM
Moderator: Melanie Jorgenson, RN, BSN
Speaker: Renee LeBlanc, RN, BSN; Kimberly Waters, MSN, RN, CPHQ; Nanci
Fredrich, RN, BSN, MM
Intended Audience: Physicians, Technologists, Nurses, Managers/Supervisors
Teaching level: Intermediate
Objectives:



Enhance communication skills and creativity to create education materials
related to PBM.
Describe how everyday resources(Microsoft)can build data reports with
meaningful metrics.
Incorporate current research, case studies and available resources to
augment a PBM program.
Event Description: Patient Blood Management has become a focus at many
institutions. Program coordination is often added to a current job or a TSO/PBMC
is hired. What resources are available to use including case studies, interpreting
research studies, or even applying for funding? How best to use and analyze the
data you have to provide reports to others to show improvement? Development
of new talents including communication using a variety of media types, data
analysis and reports with meaningful metrics and current research and case
studies is essential. Accessing resources to adapt to each PBM program is a key
starting point for a successful PBM program. Learning new skills and networking
with others in similar positions can lead to development of a toolkit filled with
ideas and materials that can be adapted to the culture of an organization. This
session will include open discussion about real-life situations and solutions as
well as provide program coordinators, TSOs and PBMCs with additional tools,
skills and tricks to build a resource toolkit.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 9
(9110-LMT) Operational Excellence: Coaching the Next Generation of Problem
Solvers
Director: Mark Malone, BS, ME
Moderator: Ellen Ermer, MSE, CSSBB
Speaker: Virginia Schoffelman, MSN, RN
Intended Audience: Managers/Supervisors, CEOs/CFOs
Teaching level: Basic to Intermediate
Objectives:



Understand the improvement and coaching routine.
Discuss your role as a coach, teaching staff how to use a scientific method
for problem solving.
Demonstrate how the improvement and coaching routine can create a
culture of continuous improvement.
Event Description: The improvement and coaching routine is a method that
prepares staff to establish a daily habit in the use of scientific thinking for problem
solving. It creates a paradigm shift in thinking about the role as a leader to a
coach and the role of staff to daily problem solvers. It is how continuous
improvement can be achieved and sustained.
(9111-LMT) Risk-Based Decision-Making from Concept to Practice
Director/Moderator: Judie Leach Bennett, LLM
Speaker: Joanne Tossell, RN; George Kotsious; Padraig Williams, FACSLM,
MSc.; Margaret Fearon, MD; Alyson Svenson
Intended Audience: Managers/Supervisors, CEOs/CFOs
Teaching level: Intermediate
Objectives:



To examine the experiences in translating this RBDM framework from
theory into practice across multiple jurisdictions and cultures.
To provide case studies based on in-practice examples that demonstrate
the practical application of the RBDM framework.
To discuss approaches for integrating the RBDM Framework with
competing or complementary frameworks that impact on final decision
making for blood operators.
Event Description: This session will look at the practicality of risk-based
decision making. The emphasis of the session will be translation from theory to
practice. Focus will be on specific examples of use of the decision-making
framework including the provision of actual case studies covering more difficult
instances such as the implementation of a standardized tool across disparate
cultures and working with regulators to integrate their framework. An example
working through the online tool will also be demonstrated and the use of voting
technology will maximize audience engagement in this powerful tool.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 10
12:00 p.m. - 2:00 p.m.
(9112-S) NBF Grant Recipients' Lecture and Luncheon
Director/Moderator: Jeanne Hendrickson, MD
Speaker: Anand Padmanabhan, MD, PhD, MA; Jeffrey Carson, MD;
Mobin Karimi, MD, PhD
Intended Audience: Physicians, Scientists, Technologists, Nurses,
Managers/Supervisors, CEOs/CFOs, Perfusionists
Teaching level: Intermediate to Advanced
Objectives:



Discover how the NBF Scientific Research Grants Program has advanced
original research for early-career investigators in the areas of blood
banking, transfusion medicine, cellular therapies and patient blood
management.
Assess and appreciate how NBF-funded exploratory research activities
have driven developments that improve patient and donor care.
Explore cutting-edge discoveries that will shape transfusion medicine,
cellular therapies and patient blood management in the future.
Event Description: This lecture showcases the research activities of three earlycareer transfusion medicine and cellular therapies investigators who are utilizing
or have utilized NBF grant funding to develop their investigations into highly
productive transfusion medicine, cellular therapies or patient blood management
research programs. The NBF Award for Innovative Research (formerly the David
B. Pall Prize for Innovative Research and the Jack Latham Memorial Award for
Innovative Research) will be awarded at this luncheon to a previous NBF grant
recipient who has developed his/her studies into high-profile innovative research
with substantial impact that may ultimately lead to improving patient outcomes.
This year the award is supported by Blood Systems, Inc. Enjoy a delicious lunch
while the scientists discuss their latest research with a focus on the role their
findings will play in driving the future of transfusion medicine, cellular therapies
and patient blood management. Time for questions and informal discussion will
be provided. This luncheon is complimentary to all attendees registered for the
full meeting on Saturday, Oct. 22 only. A ticket is required to attend and seating
is limited. Please check the appropriate box during your Annual Meeting
registration process.
(9113-TC) Apheresis Luncheon: Expert Guidance on Dealing with Challenging
Apheresis Procedures
Director: Joseph Schwartz, MD, MPH
Moderator: Tina Ipe, MD, MPH
Speaker: Meghan Delaney, DO, MPH; Huy Pham, MD, MPH; Lance A. Williams,
MD
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 11
Intended Audience: Physicians, Technologists, Nurses, Managers/Supervisors
Teaching level: Basic to Intermediate
Objectives:



Outline how to approach an apheresis consult.
Review examples of challenge issues in pediatric apheresis management.
Discuss the challenges and urgency of red blood cell exchange
procedures.
Event Description: Therapeutic apheresis is used to treat many disorders. The
American Society for Apheresis (ASFA) publishes evidence-based guidelines
every 3 years to assist apheresis practitioners in the rationale, technical, and
management of apheresis patients. Nonetheless, the guidelines provide limited
guidance on the timing of the procedure. For example, category I indications do
not always require urgent treatment. In this session, a summary of the ASFA
guidelines and a review of how to perform an apheresis consult will be provided.
Furthermore, case studies of different emergent apheresis indications will be
used to outline the approach as well, as the technical challenges in the
management of emergent or technically challenging patients. Specifically, fluid
balance considerations in emergent adult and pediatric apheresis procedures as
well as indication and urgency for red blood cell exchange will be discussed.
2:00 p.m. - 3:30 p.m.
(9114-S-CT) Immune Tolerance: Combined Cellular and Organ Transplantation
Director/Moderator: Thomas Spitzer, MD
Speaker: Joseph Kiss, MD; Thomas Spitzer, MD; Tatsuo Kawai
Intended Audience: Physicians, Scientists, Technologists, Nurses
Teaching level: Intermediate to Advanced
Objectives:



To understand the principle of immune tolerance and how it is being
applied clinically.
To understand the biologic basis of tolerance induction.
To appreciate the range of clinical applications for tolerance protocols.
Event Description: Immune tolerance, with avoidance of the need for systemic
immunosuppression after organ transplants has long been considered the "Holy
Grail" of transplantation. This event will explore the biologic basis of and clinical
applications for tolerance induction strategies with a focus on tolerance through
hematopoietic chimerism. The three lectures will describe pre-clinical models of
tolerance induction that led to tolerance protocols and the combined bone
marrow and organ (kidney) and composite tissue transplants that have been
performed in patients with and without an underlying malignancy. Possible
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 12
mechanisms of tolerance induction, both central and peripheral, that has been
achieved in those patients will be described. Future tolerance induction strategies
may include other organ or tissue transplants and delayed bone marrow
transplant approaches.
(9115-S) Don't We Know it All Yet? What's New in Hemostasis?
Director/Moderator: Maureane Hoffman, MD, PhD
Speaker: Alisa Wolberg, PhD, FAHA; Robert Flaumenhaft, MD, PhD;
Maureane Hoffman, MD, PhD
Intended Audience: Physicians, Scientists
Teaching level: Intermediate to Advanced
Objectives:



Become aware of the different states of platelet activation and the role
they may play in hemostasis and thrombosis.
Appreciate the role of coagulation factor XIII and RBC in the structure and
stability of hemostatic and thrombotic blood clots.
Appreciate the emerging information on the role of thiol isomerases in
hemostasis and thrombosis.
Event Description: This program will cover selected topics where recent data is
changing our concepts of how hemostasis is regulated. Dr. Maureane Hoffman
will review recent work on the different states to which platelets can be activated,
leading tp expression of different levels of hemostatic activity. This work has led
to a better understanding of how platelet responses are "fine tuned". Dr. Alisa
Wolberg will review the recent work of her lab and others on the role fibrinogen
and FXIII function in thrombus formation and structure, and role that RBC
retention plays in clot stability. Dr. Robert Flaumenhaft will present his work on
the procoagulant activity of protein disulphide isomerase (PDI), its role in
thrombosis and the therapeutic potential of PDI inhibitors.
(9116-S) Hot Topic: Zika and Its Impact to Transfusion (SAM)
Director/Moderator: Susan Stramer, PhD
Speaker: Lisa Pate, MD, JD; Lyle Petersen, MD, MPH; Luiz Amorim, MD; Jeff
Linnen, PhD
Intended Audience: Physicians, Scientists, Technologists, Nurses
Teaching level: Intermediate to Advanced
Objectives:


To review the virology, epidemiology, clinical significance and public
health implications of Zika virus.
To describe the impact of Zika virus in Brazil.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 13

To describe the testing strategies that have been introduced in the US and
a summary of their findings to date.
Event Description: With the introduction of Zika virus into the Americas,
associated explosive outbreaks in Brazil and other countries worldwide since
2013, demonstration of Zika virus RNA in blood donors, documented transfusion
transmission, linkage to microcephaly, Guillain—Barré and other nervous system
disorders, strategies are needed to protect the safety of the blood supply from
this primarily mosquito-borne flavivirus. This session will describe background
information on the characteristics of the virus, its epidmiology, clinical outcomes
associated with viral infection and public health considerations followed by a
description of the outbreak in Brazil and lastly interventions that have been
introduced in the United States using investigational NAT assays including
experience to date. A question and answer session will follow the formal
presentations.
(9119-TC) Implementing Pathogen-Reduced Apheresis Platelets
Director/Moderator: Bill Flegel, MD
Speaker: Sherry Sheldon, MT(ASCP)SBB; Dayand Borge, MD, PhD;
Jean-Pierre Allain, MD, PhD
Intended Audience: Physicians, Scientists, Technologists,
Managers/Supervisors, CEOs/CFOs
Teaching level: Basic to Intermediate
Objectives:



Describe actual implementation examples at blood centers and hospitals.
Review regulatory/quality assurance requirements and the education of
clinical staff before introducing pathogen-reduced platelets.
Evaluate a technology of pathogen-reduction beyond platelets & plasma.
Event Description: Pathogen-reduction technologies for platelet and plasma
components are approved for clinical use in the US since 2014. The
implementation of the new technologies may raise questions and pose
challenges. Knowledge and careful planning of the regulatory and quality
assurance aspects will facilitate the process of introducing pathogen-reduction at
blood centers. Early involvement and educating the clinical users during the
implementation process is critical. There will be plenty of opportunity for audience
participation and questions.
(9121-TC) Transfusion Related Circulatory Overload: What's New?
Director: Jay Raval, MD
Moderator: Aaron Tobian, MD, PhD
Speaker: Jay Raval, MD; Chester Andrzejewski, PhD, MD; Ian Welsby, MB BS
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 14
Intended Audience: Physicians, Scientists, Technologists, Nurses,
Managers/Supervisors
Teaching level: Intermediate to Advanced
Objectives:



Describe the pathophysiology, incidence with different blood components,
and patient risk factors associated with Transfusion Associated Circulatory
Overload (TACO).
Recognize how utilization of informatics and the electronic medical record
system can positively impact the occurrence of TACO.
Explain what diagnostic and therapeutic interventions/strategies (and the
strength of associated evidence for these interventions/strategies) are
available to decrease/prevent TACO reactions.
Event Description: Transfusion Associated Circulatory Overload (TACO) is a
frequently underreported complication of transfusion that is currently the second
most common cause of transfusion-related fatalities. In this session, TACO's
pathophysiology, patient's at high-risk of developing TACO, and its incidence of
occurrence with different blood components will be covered. Use of informatics
technology and the electronic medical record as tools to combat the occurrence
of TACO in real time will be discussed. Lastly, the different diagnostic and
therapeutic interventions/strategies to treat/prevent TACO and associated
evidence will be explored.
(9122-QE) Practical Aspects of Big Data in Patient Blood Management
Director/Moderator: Mark Ereth, MD
Speaker: Steven Frank, MD; Jamison Feramisco, MD
Intended Audience: Physicians, Technologists, Nurses, Managers/Supervisors
Teaching level: Intermediate to Advanced
Objectives:



Understand the necessity of actionable analytics in PBM.
Understand the integration of Big Data into PBM programs.
Appreciate the derivation of hyper-personalized transfusion practices via
Big Data.
Event Description: Didactic presentations with speaker moderation and
attendee interaction.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 15
(9123-QE) CAP Proficiency Testing: Review of Test Performance & Future
Directions
Director: Karen King, MD
Moderator: Yara Park, MD
Speaker: Alexandra Valsamakis, MD, PhD; Evelyn Lockhart, MD; Nicole Zantek,
MD, PhD
Intended Audience: Physicians, Technologists, Managers/Supervisors
Teaching level: Intermediate to Advanced
Objectives:



To understand the regulations that require PT testing, which tests are graded
and ungraded, and the implications of the regulations.
To learn from the collective experience of PT surveys that show issues with
test performance
To gain exposure to the newest offerings from CAP for transfusion service
and blood supplier laboratories.
Event Description: In this session, members of the College of American
Pathologists (CAP) Transfusion Medicine Resource Committee will review the
current state of proficiency testing regulations and objectives. Issues with specific
PT surveys will be discussed, including fetal bleed detection, and infectious
disease testing. New offerings for PT will be highlighted to show the
advancement of transfusion service laboratory capabilities.
2:00 p.m. - 5:30 p.m.
(9117-TC) Sally Frank Memorial Award and Lectureship
Director: Patricia Whitacre, MT(ASCP)SBB
Award Description: The Sally Frank Memorial Award and Lectureship was
established in 1982 in memory of Ms. Sally Frank and her dedication to red cell
serology and education. This award recognizes an individual who is, or has been,
a medical technologist involved with these fields and has demonstrated quality
research, teaching and/or service abilities in the technical aspects of
immunohematology.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 16
(9118-TC-HEM) Aspectos Practicos e Innovadores de la Hemovigilancia GCAMTAABB
Director: Nancy Benitez, MHS (ASCP) SBB
Moderator: Graciela Leon, Hematologist, MD
Speaker: Graciela Leon, Hematologist, MD; Eduardo Muniz Diaz, Director Medico,
Hematologo; Cesar Cerdas-Quesada, Director Medico- Hematologo
Intended Audience: Physicians, Scientists, Technologists, Nurses,
Managers/Supervisors
Teaching level: Intermediate
Objectives:



Demostrar los beneficios de la Hemovigilancia en la seguridad de donantes de
sangre, productos sanguneos y pacientes.
Revisar el propsito de los estndares y guas Internacionales, asi como los
requisitos de calidad para la implementacin de un programa de Hemovigilancia.
Revisar y discutir casos prcticos para ejemplificar el programa de
Hemovigilancia.
Event Description: En este taller expertos en sistemas de Hemovigilancia revisaran
como la implementación de este programa aumenta la seguridad de los pacientes,
donantes de sangre y productos sanguíneos. Se revisara el uso de técnicas de análisis
y monitoreo del proceso. Los Estándares, historia y guías de calidad serán revisados y
aplicados a casos prácticos interactivos
(9120-TC) Thrombotic Microangiopathies: Current Treatments and Future
Directions
Director/Moderator: Kenneth Friedman, MD
Speaker: Kenneth Friedman, MD; Marisa Marques, MD; X Long Zheng, MD,
PhD; Bradley Dixon, MD
Intended Audience: Physicians, Scientists, Technologists, Nurses
Teaching level: Intermediate
Objectives:



Be able to select an appropriate clinical and laboratory evaluation of a patient
presenting with symptoms suggestive of thrombotic microangiopathy.
Understand the current recommended therapy for a patient with thrombotic
thrombocytopenic purpura and be aware of emerging therapies.
Be able to triage patients presenting with signs consistent with a diagnosis of
atypical hemolytic uremic syndrome and understand treatment alternatives.
Event Description: Advances in the understanding of the pathogenesis of
thrombotic microangiopathies have improved our ability to distinguish thrombotic
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 17
thrombocytopenic purpura (TTP) from atypical hemolytic uremic syndrome (aHUS).
Delineation of the role of ADAMTS13 in the pathogenesis of TTP affords improved
diagnosis and the potential for new therapeutic options. aHUS remains a clinical
diagnosis, but improved understanding of the role of complement has resulted in
replacement of plasma exchange therapy by targeted drug treatment for
appropriately selected patients. During this session, clinical and laboratory
evaluation of these thrombotic microangiopathies will be reviewed as well as current
therapies and emerging therapeutic options.
(9124-LMT) Armed Services Blood Program
Director: Roland Fahie, Medical Service Corps, USN
Moderator: Air Force Lieutenant Colonel Jerome Vinluan, Deputy Director
Operations, Armed Services Blood Program
Speaker: Roland Fahie, Medical Service Corps, USN
Intended Audience: Physicians, Scientists, Technologists,
Managers/Supervisors
Teaching level: Intermediate
Objectives:



Identify the operations and reach of the military blood program through
innovation research and development, humanitarian assistance, and
theater blood support.
Identify strategic business objectives driving major developments in the
Armed Services Blood Program.
Report on military blood program medical support efforts regarding
overseas contingency operations.
Event Description: This session will provide the audience and members with
dynamic insight into the strategic business objectives that drive military blood
program operations around the world. United States Armed Services Blood
Program leaders, including our Joint Blood Program Officers from our Combatant
Commands will showcase recent and ongoing wartime and humanitarian blood
program support. In addition, a discussion on research and development
designed to bring blood and blood products closer than ever to the point of injury,
will be presented by those individuals most closely involved in this critical
mission. The session will close with the Lifetime Achievement Award ceremony,
which honors awardees for lifelong, transformative contributions to the Armed
Services Blood Program.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 18
(9125-LMT) Change Readiness: One Way or Another
Director/Moderator: Peggy McAleer, BS, CQA(ASQ)
Speaker: Dan Waxman, MD; Morris Connie, MM, MT(ASCP)BB,HP
Intended Audience: Physicians, Technologists, Nurses, Managers/Supervisors,
CEOs/CFOs
Teaching level: Basic to Intermediate
Objectives:



Explore ways management can facilitate change readiness.
Describe methods to help empower employees to gain productivity and
efficiency.
Create an environment for cooperation rather than contention.
Event Description: In every aspect of business, change seems to be the only constant
for employees in the age of reorganization, redeployment and restructure. With the vast
changes and uncertainty hanging over the healthcare industry now, more than ever,
blood banks must be lean, mean, changing machines. Change will happen, one way or
another. Successful, timely change readiness requires skilled direction and cooperation
from all levels of the organization. Empowered employees can bring about
improvements in quality and productivity while improving morale. Experienced leaders
in the industry will discuss both the challenges of the current environment as well as
effective methods they utilize to drive successful changes.
4:00 p.m. - 5:30 p.m.
(9126-TC-CT) Cellular Therapy for Neurological Diseases
Director/Moderator: Michele Sugrue, MS, MT(ASCP)SBB
Speaker: Duane Mitchell, M.D., Ph.D.; Joanne Kurtzberg, M.D.
Intended Audience: Physicians, Scientists, Technologists, Nurses
Teaching level: Intermediate
Objectives:



Review historical background and laboratory approaches for cellular therapy
in neurological diseases.
Discuss the current status of cellular therapy and associated clinical trials
neurological diseases.
Describe innovative applications of immunotherapy to treat malignant brain
tumors.
Event Description: Recent advances in cellular therapy have been found to be
promising therapeutic options for the treatment of numerous neurologic diseases.
Pre-clinical cellular therapy studies in neurodegenerative disorders such as
Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis as
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 19
well as neurovascular impairment conditions (i.e., stroke) have had encouraging
results and are quickly moving into clinical trials. In addition, harnessing the
potential of cellular immunotherapy, studies have demonstrated that one may
drive the immune system to attack neuro-derived brain cancer cells. In this
program, speakers will review the strategies and methodologies for these
innovative approaches. The status of translational investigations and current
clinical trials will be discussed. In addition, future modalities and approaches to
developing curative therapies will be addressed.
(9127-QE) You did WHAT?!? Error Management: Transforming Lemons into
Limoncello
Director/Moderator: Theresa Downs, MT(ASCP)SBB, CQA(ASQ)
Speaker: Sheri Goertzen, MT(ASCP)BB, CLS(CA), CQA(ASQ);
Maureen Beaton, MT(ASCP)BB, CQA(ASQ)
Intended Audience: Physicians, Technologists, Managers/Supervisors
Teaching level: Intermediate
Objectives:



Discuss the importance of error management to transfusion service operations.
Examine two error management systems to track and trend variances.
Describe ways to find and analyze mistakes/errors to improve processes and
operations.
Event Description: You have a choice...you can view an error either as an
irritation or an opportunity. This session will discuss the identification and
management of errors in a transfusion service. Learn why error management is
critical to quality operations, how to value these learning opportunities and make
the most of them. Examples of various tools used to capture, track and manage
errors will be shared.
(9128-QE-CT) cGMP Laboratory Basics
Director/Moderator: Yvette Tanhehco, PhD, MD, MS
Speaker: Adrian Gee, PhD; Don Siegel, MD, PhD; Yvette Tanhehco, PhD, MD,
MS
Intended Audience: Physicians, Scientists, Technologists,
Managers/Supervisors
Teaching level: Basic to Intermediate
Objectives:



Discuss the design, operation, and regulatory requirements of a cGMP
laboratory and differentiate it from a GTP laboratory.
Discuss the utility of a cGMP laboratory.
Discuss the challenges and lessons learned from opening a cGMP laboratory.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 20
Event Description: The US Food and Drug Administration (FDA) regulates the
quality of biologics and pharmaceuticals very carefully. The main regulatory
standard for ensuring a high quality product is the Current Good Manufacturing
Practice (cGMP) regulation for human pharmaceuticals. cGMP regulations
provide for systems that assure proper design, monitoring, and control of
manufacturing processes and facilities. Adherence to the cGMP regulations
assures the identity, strength, quality and purity of products. Transfusion
medicine physicians are frequently involved in the manufacture of biologics so
knowledge of the design, operation and validation of a cGMP laboratory is
paramount. This session will discuss the basic aspects of running a cGMP
laboratory.
(9129-QE) Validation 101
Director/Moderator: Regina Castor, BS, MT(ASCP)SBB
Speaker: Rosemary Steuber, MT, SBB(ASCP)
Intended Audience: Scientists, Technologists, Managers/Supervisors
Teaching level: Basic to Intermediate
Objectives:



Describe the purpose of validation as it relates to transfusion services.
Define regulatory requirements for validation (including Installation,
Operational Qualification, and Performance Qualification).
Explain the process of validation and describe common pitfalls to avoid.
Event Description: This session will introduce validation to those who are new
to writing and/or executing validation in the transfusion world. It will review
regulatory requirements, present scenarios, and describe some pitfalls to avoid in
the validation process. Primary emphasis will be on instrumentation but content
will also apply to other equipment and processes.
(9130-LMT) Balancing Technical and Administrative Functionality: The Making of
the Next Generation of Laboratory Leaders
Director: Steven Armstong
Moderator: Karafa Badjie, MS, MLS(ASCP)SBB, BMLSc
Speaker: Ricardo Sumugod, MS, MT(ASCP)SBB; Steven Armstrong, MSHA,
MT(AMT), SBB(ASCP), FACHE; Karafa Badjie, MS, MLS(ASCP)SBB, BMLSc
Intended Audience: Technologists, Managers/Supervisors
Teaching level: Basic to Intermediate
Objectives:


Provide tools and examples on how to balance technical and leadership
development.
Provide ideas on how to successfully handle the rapid rate of change in
healthcare today.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 21

Provide basic financial management tools used for providing fiscally sound
laboratory leadership.
Event Description: In the modern day laboratory, leadership development must
be seen as much as a priority as technical skill enhancement. Balancing the
technical knowledge to be a great laboratorian, while also providing individuals
with the business and leadership skills needed to be successful supervisors and
managers, is a challenge in the constantly changing healthcare environment.
This session will provide ideas and examples on how to successfully engage and
develop new staff members both technically and as leaders for succession
planning. Technical and staff development, change management techniques,
and fiscal accounting tools will be discussed while providing examples on their
use from the leadership perspective.
(010A) Scientific Oral Abstract Session: Cellular Therapies and Immunotherapies
(010B) Scientific Oral Abstract Session: Donor Recruitment, Retention and
Adverse Events
(010C) Scientific Oral Abstract Session: Transfusion-Transmitted Infectious
Diseases: Zika Virus
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 22
SUNDAY, OCTOBER 23, 2016
8:30 a.m. - 9:15 a.m.
(9201-S) Emily Cooley Memorial Award and Lectureship: From Cytokines to
Pragmatic Designs: Changing Paradigms
Director/Moderator: Jose Cancelas, MD, PhD
Speaker: Nancy Heddle, MSc, FCSMLS(D)
Intended Audience: Physicians, Scientists, Technologists, Nurses
Teaching level: Intermediate
Objectives:



To understand how twelve patients informed the pathophysiology of febrile
non hemolytic transfusion reactions.
To explore the stored blood controversy and the role of big data and
pragmatic research designs to determine whether stored blood affects
patient outcomes.
To identify important lessons learned from over 25 years of involvement in
clinical research.
Award Description: This award began as a lectureship in 1963 and was
designated as a Memorial Award in 1983. The person who receives this award
shall have demonstrated teaching ability and have made a major contribution to
the field of transfusion medicine or cellular therapies.
8:30 a.m. - 10:00 a.m.
(9206-QE-CT) Nonconforming Cellular Therapy (CT) Products- What Do We Do
Now?
Director/Moderator: Lisa Phillips Johnson, MT(ASCP)SBB, CQA, CMQ/OE,
RAC
Speaker: Hanh Khuu, MD; Lisa Phillips Johnson, MT(ASCP)SBB, CQA,
CMQ/OE, RAC
Intended Audience: Physicians, Scientists, Technologists,
Managers/Supervisors
Teaching level: Basic to Intermediate
Objectives:


Describe what nonconforming products, services or materials are in CT
setting.
Provide an overview of the regulatory and quality system requirements
from FDA and accrediting agencies for 351 and 361 products.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 23

Using real-life scenarios, show how problems encountered during
manufacturing can be addressed and demonstrate how process
improvements resulted from these lessons.
Event Description: During the manufacturing process of cellular therapy
products, from collection and cryopreservation to natural killer cell products,
things may go awry. This session will outline the regulatory and quality system
requirements in 351 and 361 product settings and operational systems needed to
support the management of nonconforming products, services and materials.
Several real-life scenarios will be discussed to describe what went wrong and
how to address these problems in real time, as well as demonstrate how these
headaches can be opportunities for process improvement, overall.
(9207-LMT ARS) Operational Excellence Practitioner Program: Building Your
Leadership's Bench Strength in Continuous Improvement
Director: Mark Malone, BS, ME
Moderator: Joanne Voordeckers, ASQ CSSBB
Speaker: Sherri Cyrus, MT(ASCP)SBB ; Joanne Voordeckers
Intended Audience: Managers/Supervisors, CEOs/CFOs
Teaching level: Intermediate to Advanced
Objectives:



Learn how to accelerate your Operational Excellence journey with the
addition of part-time OE Practitioners.
Learn about a program that will help you to develop your leadership bench
strength in continuous improvement methodologies.
Hear a real-life case study of the challenges and successes of the OE
Practitioner role.
Event Description: Leaders are selected to work part-time in a role called OE
Practitioner for a period of 2 years. They attend special training to learn
continuous improvement tools and understand the culture change necessary to
sustain gains made by the OE initiative. So as not to over-burden any one
individual, the time the Practitioner spends on OE is back-filled by employees
who desire to grow into their next positions. As teams become engaged in the
daily problem-solving improvement routines and huddles associated with
Operational Excellence, it helps them to know they have a knowledgeable "boots
on the ground" leader in the OE Practitioner to assist them in practicing their
new-found skills. This is particularly true in environments with multiple facilities
and the seemingly universal issue of limited resources. These leaders are getting
something out of it, too, besides more work. They will have developed a deeper
understanding of OE principles so that as they work in their full-time role, they
are in a better position to foster and sustain the culture change. As years go by,
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 24
the number of these leaders will grow and be key to changing the culture of the
organization.
8:30 a.m. - 12:00 p.m.
(9203-TC-RC ARS) AABB Donor History Questionnaire
Director/Moderator: Sheila O'Brien, PhD, RN
Speaker: Sheila O'Brien, PhD, RN; Mary Townsend, MD; Yvette Miller, MD;
Sheila O'Brien, PhD, RN
Intended Audience: Physicians, Technologists, Nurses, Managers/Supervisors
Teaching level: Basic to Intermediate
Objectives:



To present highlights of the revised AABB Donor History Questionnaire
and accompanying materials including changes to comply with the final
rule.
To explore the social, emotional and practical issues of determining the
gender of donors who do not self-identify as their birth gender. Gender
identification is necessary for gender specific DHQ questions.
To explain the rationale for donor deferral for various medications
identified using the DHQ and Medication Deferral List, and discuss
practical approaches to balancing the ever-increasing number of new
drugs on the market while keeping the process simple enough for donors
to provide complete and accurate histories.
Event Description: In 2016 a full revision of the AABB Donor History
Questionnaire (DHQ) and accompanying materials was completed (Version 2.0),
and is compliant with the May 2015 Final Rule, “Requirements for Blood and
Blood Components Intended for Transfusion or for Further Manufacturing Use,”
and the December 2015 FDA Guidance “Revised Recommendations for
Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and
Blood Products.” In this session the AABB Donor History Task Force will present
highlights of the revised DHQ and accompanying materials. Key transgender
issues will be identified and approaches in different jurisdictions will be discussed
to assist facilities as they develop their own policies to address application of the
gender-specific questions. The rationale behind the inclusion of various
medications for deferral will be explained and the new approach in the AABB
DHQ and Medication List will be presented.
(9205-QE) SBB/BB Exam Review
Director/Moderator: Jayanna Slayten, MS, MT(ASCP)SBBcm
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 25
Speaker: Jayanna Slayten, MS, MT(ASCP)SBBcm; LeeAnn Walker, MEd,
MT(ASCP)SBB; Lorraine Blagg, MA, MLS(ASCP)SBB; Stacey Alvey, MEd,
MT(ASCP)SBB; Kate Hernandez, MT(ASCP)SBB
Intended Audience: Physicians, Technologists, Managers/Supervisors
Teaching level: Intermediate to Advanced
Objectives:


Review SBB and BB exam requirements and the content outlines for each
exam.
Provide references for each content area. Highlight pertinent information
that may be covered on these exams. Discuss helpful hints for studying for
and taking these exams.
Event Description: It would be impossible to present all the information needed
to pass the SBB or BB exams in a three-hour program. This program will provide
a roadmap for those preparing for the BB or SBB exam. Content areas of the
exams will be highlighted with emphasis on where to find information required for
successful completion of these exams. A study guide with references for each
section will be provided to attendees of this session.
(9204-TC ARS) Chief Technologist SIG
Director: Gary Pawlak, MT(ASCP)
Moderator: Terri Hintz, MT(ASCP)SBB, CQA(ASQ)
Speaker: Suzanne Butch, MA, MLS(ASCP)SBB, CM; Diane Schafer, MSA,
MT(ASCP)SBB; Melanie Champion, CQA(ASQ), MBA, MT(ASCP)SBB; Theresa
Downs, MT(ASCP)SBB, CQA(ASQ); Doris Ratcliff, MSHCM, MT(ASCP)SBB;
Christine Terranova, BS, MT(ASCP)
Intended Audience: Technologists, Managers/Supervisors
Teaching level: Intermediate
Objectives:



Discuss the strategies of RHD genotyping for pregnant women and other
females of child bearing age who exhibit a Serologic Weak D phenotype
or discrepant Rh typing.
Discuss implementation strategies and hurdles of maintaining a 7-day
platelet inventory.
Identify the challenges of implementing and testing a Disaster Plan for the
Blood Bank.
Event Description: This session presents and discusses topics related to
transfusion services. Short presentations and panel discussions with audience
participation make up the first half of the session. The second half is devoted to
discussion of questions posed to the audience using an audience response
system.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 26
9:15 a.m. - 10:00 a.m.
(9202-S) Tibor Greenwalt Memorial Award and Lectureship
Director/Moderator: Jose Cancelas, MD, PhD
Speaker: Parviz Lalezari, MD
Intended Audience: Physicians, Scientists, Technologists, Nurses
Teaching level: Intermediate
Objectives:

Learn the historical developments that made possible the identification
and characterization of neutrophil antigens and their role in common forms
of antibody-mediated neonatal neutropenia.
Award Description: This award honors Tibor Greenwalt, MD, who was the first
registrant at the first AABB Annual Meeting and founding editor of TRANSFUSION. The
award recognizes an individual who made major scientific or clinical contributions to
hematology, transfusion medicine or cellular therapies and succinctly communicated
these advances. The title of Dr. Lalezari’s presentation is: Immunology of NeutrophilSpecific antigens.
10:30 a.m. - 12:00 p.m.
(9208-S) TTD II: Pathogen-Reduction Technology — Impact on Blood Operations
and Future Developments
Director/Moderator: Steve Kleinman, MD
Speaker: Heather Pidcoke, MD, PhD; Harvey Klein, MD; Richard Benjamin, MD;
James AuBuchon, MD, FCAP, FRCP(Edin)
Intended Audience: Physicians, Scientists, Technologists, Nurses
Teaching level: Intermediate to Advanced
Objectives:
 Review the general issues related to decisions to implement pathogen reduction
technology
 Review the use of PRT and other potential alternatives to decrease the risk of
bacterial contamination from platelet transfusion
 Review status of R&D clinical trials for red cell and whole blood pathogen
reduction.
Event Description: Pathogen reduction technologies have the potential to radically alter
our approach to providing safe transfusion. Their practical application to create pathogenreduced blood components raises a variety of questions and poses considerable
challenges. The value of directly diminishing or even eliminating the residual risk of
bacterial contamination as well as that of current and future viral and other pathogens'
threats while potentially eliminating some redundant tests are important goals.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 27
This workshop will provide a general overview of issues related to PRT and update
studies on bringing red cell/whole blood pathogen reduction technologies to commercial
use.
(9209-S-CT) Gene Therapy is Back
Director/Moderator: Jose Cancelas, MD, PhD
Speaker: Brian Sorrentino, MD; Punam Malik, MD
Intended Audience: Physicians, Scientists, Technologists, Nurses
Teaching level: Intermediate to Advanced
Objectives:

Learn how current gene therapy protocols are being implemented in
clinical trials for therapy in congenital immunodeficiencies and
hemoglobinopathies.
Event Description: First-hand experience of leaders in the field of gene
therapies. The session will update the audience on the current status of gene
therapies in immunodeficiencies and hemoglobinopathies and what are the
current challenges (biological, technical and regulatory) for the extension of these
trials to large cohorts of patients.
(9210-S) Mechanisms of Antibody-Mediated Hemostatic Diseases
Director/Moderator: Kenneth Friedman, MD
Speaker: Jacob Rand, MD; Anand Padmanabhan, MD, PhD, MA
Intended Audience: Physicians, Scientists, Technologists, Nurses
Teaching level: Intermediate to Advanced
Objectives:



To understand currently proposed pathogenic mechanisms in two
immune-mediated thrombophilic conditions, antiphospholipid syndrome
and heparin-induced thrombocytopenia.
Be able to propose a diagnostic evaluation of a patient who might have
antiphospholipid syndrome and discuss the limitations of current assays.
Be able to select currently available lab studies to evaluate a patient for
heparin-induced thrombocytopenia and anticipate advances in the
diagnosis of that condition.
Event Description: Immune mediated thrombophilic conditions such as
antiphospholipid syndrome (APS) and heparin-induced thrombocytopenia (HIT)
are characterized by the presence of pathologic autoantibodies in patient blood.
The clinical manifestations of APS include vascular thrombosis and pregnancy
complications. Autoantibodies that recognize phospholipid-binding proteins are
implicated in this disease, but the exact mechanism by which these antibodies
trigger thrombosis remains unclear. Autoantibodies to heparin-PF4 complex
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 28
activate platelets, monocytes and endothelium in HIT, however the mechanisms
that trigger the immune response are still being elucidated and recent technical
improvements may allow enhanced diagnostic accuracy. In this session we will
learn of recent findings related to mechanism of disease and implications related
to diagnosis and management of these two thrombotic immunologic conditions.
(9211-TC-HEM ARS) Stump the Hemovigilance Experts
Director/Moderator: Barbee Whitaker, PhD
Speaker: John Roback, MD, PhD; Pierre Robillard, MD; Kamille West, MD
Intended Audience: Physicians, Scientists, Nurses, Managers/Supervisors
Teaching level: Intermediate to Advanced
Objectives:



Identify adverse reactions by their case definitions.
Participate in coding challenging case reports using the national
definitions.
Discuss imputability and learn about the relationship between transfusions
and reactions.
Event Description: Come for a return engagement of the Hemovigilance
Experts! This event provides the opportunity to participate in the analysis and
coding of transfusion reactions using the definitions adopted by the CDC National
Healthcare Safety Network - Hemovigilance Module. Bring or submit cases from
your experience (complex or simple) and discuss categorization with the experts.
(9212-TC ARS) Perspectives on Massive Transfusions: Surgeons, Blood Centers
and the Impact on the Community
Director/Moderator: Claudia Cohn, MD, PhD
Speaker: Jed Gorlin, M.D., M.B.A.; James Harmon, MD; Jeffrey Kahn, PhD,
MPH
Intended Audience: Physicians, Technologists, Nurses, Managers/Supervisors,
CEOs/CFOs, Perfusionists
Teaching level: Basic to Intermediate
Objectives:



A bedside view of massive transfusions: Do surgeons and intensivists
need help from the blood bank?
A view of massive transfusions from the donor center: Can a single
massive transfusion threaten the blood supply for other hospitals in the
region?
An ethics perspective on massive transfusions: The challenge of
balancing the needs of individual patients and maintaining an available
resource for the community.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 29
Event Description: This section will explore massive transfusion protocols from
three perspectives: a surgeon trying to save a bleeding patient; a medical
director of a blood center, who is trying to balance the demands from multiple
hospitals while a single MTP drains the inventory; and finally an ethicist, who will
explore the allocation of scarce resources in medicine. This section will ask who
is responsible for ending an MTP when the effort to keep one patient alive
exceeds normal limits. We will also look at the larger role of the blood bank
during MTPs.
(9213-TC ARS) An Evidence Based/Consensus Guideline from the International
Collaboration for Transfusion Medicine Guidelines (ICTMG): Management
Strategies of Fetal and Neonatal Alloimmune Thrombocytopenia
Director: Lani Lieberman, MD
Moderator: Michael Murphy, MD, FRCP, FRCPATH, FFPATH (M.)
Speaker: James Bussel, MD; Dick Oepkes; Lani Lieberman, MD; Taman
Bakhoul; Jens Kjeldsen-Kragh, MD, PhD
Intended Audience: Physicians, Scientists, Technologists, Nurses
Teaching level: Intermediate to Advanced
Objectives:



Review antenatal treatment options for women with a past history of a
FNAIT pregnancy including steroids and intravenous immunoglobulin and
intrauterine transfusion.
Review the treatment options for neonates diagnosed with FNAIT.
Present results of the systematic review related to the use of HPA
alloantibody titres to assess the presence and severity of FNAIT.
Event Description: Controversies regarding the optimal antenatal management,
postnatal treatment and predictors of severity of fetal and neonatal alloimmune
thrombocytopenia persist. Practice varies internationally and often depends on
expert consensus. The International Collaborative in Transfusion Medicine will
present results of their systematic reviews, and discuss recommendations
regarding treatment strategies.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 30
(9214-TC-CT) How to Handle the Surge in Clinical Trials in the Cellular Therapy
Laboratory
Director/Moderator: Lizette Caballero, MLS (ASCP)CM
Speaker: Lizette Caballero, MLS (ASCP)CM; Ronit Slotky, PhD, MSc; Jolynn
Procter, MEd, BS, MT&SBB(ASCP), CQA (ASQ)
Intended Audience: Physicians, Scientists, Technologists
Teaching level: Basic to Intermediate
Objectives:



Discuss the challenges of addressing discrepancies between provider's
procedure and in-house procedure, combing existing labelling system with
outside provider's requirements, and employee training.
Review the regulatory challenges. Discuss the need to ensure that FDA
and local government licensure covers the type of cells used in the
investigational protocol, and examine the challenge of ensuring HIPPA
compliance while sharing patients' private information with outside
providers.
Review assessment of investigational studies costs and re-imbursement.
Event Description: This session will discuss the complexity of incorporating
multiple clinical trials, such as corporate or multicenter sponsored, into the
routine cellular therapy laboratory environment. It will provide an overview of the
logistical, regulatory, and resources aspects. The discussion will review the
process from initial protocol review, site initiation visit, employee training,
labelling and documentation, to budgetary challenges.
(9215-QE) Effective Communication Between the Collection Facility, the Cell
Manufacturing Laboratory, the Transfusion Service and the Clinician
Director/Moderator: J. Wade Atkins, CQA(ASQ), MS, MT(ASCP)SBB
Speaker: Michael Linenberger, MD; Karen King, MD; Kamille West, MD; David
Stroncek, MD
Intended Audience: Physicians, Scientists, Technologists, Nurses,
Managers/Supervisors
Teaching level: Intermediate to Advanced
Objectives:



Describe compliant and efficient ways to handle unusual situations that
may arise in screening, procurement, manufacturing or administration of
cellular therapy products.
Identify internal system resources that may be consulted to help navigate
unusual circumstances in Cellular Therapies.
List effective communication strategies to bridge different disciplines that
must work together to ensure quality outcomes when using Cellular
Therapy Products.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 31
Event Description: The session will use a case study format to present unusual
circumstances in one or more areas of Cellular Therapy. A panel of
representatives including areas of donor eligibility determination, procurement,
manufacturing, and clinical use as well as representative for transfusion support
will discuss the aspects of the cases. The moderator and panel encourage
audience participation for engaged learning.
(9216-LMT-CT) Hemphill-Jordan Leadership Award and Lectureship
Director: Mary Lieb, BS, MT(ASCP)SBB, CQA(ASQ)
Award Description: This award honors leaders from the transfusion medicine
and cellular therapy community. The award recognizes an individual who has
made significant contributions in the areas of administration, quality programs,
law and/or government affairs. The individual has demonstrated leadership
qualities and a consistent willingness to lend his/her expertise to his/her peers.
The award may recognize one particular act or an accumulation of contributions
throughout many years.
12:00 p.m. - 2:00 p.m.
(9238-S-CT) Cellular Therapies Sizzling Topics Luncheon: New Frontiers in
Cellular Therapy
Director: David Stroncek, MD
Speakers: Julia Goldstein, MD; Elina Linetesky, PhD; Kelley Capocelli, MD;
Andrew Fesnak, MD
Intended Audience:
Teaching level:
Event Description: Cellular therapies are reaching new frontiers. The range of
cells utilized and methods of collection and manufacture are critical to optimizing
function in clinical applications. Regulatory demands also guide how therapies
should be developed. This session will address optimizing collection of MNCs, an
important source of therapeutic cells, from both adults and children for cancer
treatment. In addition, the manufacture of pancreatic cells being pursued as a
means to restore physiological beta cell function in patients with diabetes will be
presented in the context of regulatory strategies and outcomes. Presentations of
the latest information ─ with attendee participation─ should make this luncheon
sizzle!
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 32
2:00 p.m. - 3:30 p.m.
(9217-S-CT) Clonal Analysis of Hematopoiesis
Director/Moderator: Jose Cancelas, MD, PhD
Speaker: H. Leighton Grimes, PhD; Claus Nerlov, PhD
Intended Audience: Physicians, Scientists, Technologists, Nurses
Teaching level: Advanced
Objectives:

Learn how single-cell transcriptome analysis has revolutionized our
understanding of the hierarchical organization of the stem cell and
progenitor populations that make mature blood cells.
Event Description: The final goal is to understand the molecular basis for and
spatial organization of hematopoiesis, and to use this knowledge to devise cell
based and molecular therapies that can be used to treat hematopoietic
insufficiencies and malignancies. This session will provide an update on how
single-cell genetic information is helping us understand the complex nature of
blood formation and hierarchical organization.
(9218-S) Who Are Alloantibody Responders and What Can We Do For Them?
Examining the Evidence from Human Studies & Animal Models and Discussing
Solutions to Mitigate RBC Alloimmunization in 'Responder' Patients
Director/Moderator: Christopher Tormey, MD
Speaker: Christopher Tormey, MD; Sean Stowell, MD,PhD; Stella Chou, MD
Intended Audience: Physicians, Scientists, Technologists, Nurses
Teaching level: Intermediate to Advanced
Objectives:



Familiarize participants with concept of alloantibody 'responders' in
transfusion practice, including the formulation of a working definition for
the 'responder' patient and identifying clinical & biological influences which
may contribute to the responder state.
Introduce advancements made via animal model research that have
enhanced our understanding of what governs the response to RBC
transfusions, including factors which impact the alloimmunogenicity of
transfused RBCs and how tolerance to blood group antigens may be
achieved.
Discuss alloimmunization mitigation strategies applicable to responder
patients, in particular the strengths/weaknesses of traditional options (e.g.,
blood group antigen phenotyping) and the exciting possibilities offered by
emerging technologies (e.g., genotypic antigen matching).
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 33
Event Description: Alloimmunization to RBC antigens remains a criticallyimportant issue. However, not all patients who are exposed to foreign RBCs
become alloimmunized. Based on observational studies, the concept that only a
distinct subset of individuals ('responders') may be capable of mounting an
immune response to RBC antigens has emerged. A better understanding of what
defines a responder and how they can be identified could dramatically improve
transfusion safety. Thus, the goals of this session are: 1) to familiarize
practitioners with the concept of alloantibody responders by formulating a
definition of the 'responder patient' and identifying known clinical/biological
factors associated with alloantibody development, 2) to review recent
advancements in animal models which have helped improve understanding of
the immune response to RBC transfusion, and 3) to discuss the strengths and
limitations of traditional approaches to dealing with responder patients, as well as
highlight the potential that RBC genotyping offers in mitigating alloimmunization.
(9219-S) Recent Advances in IvIg and IvIg Substitutes
Director/Moderator: Alan Lazarus, PhD
Speaker: Robert Skeate, MD; Alan Lazarus, PhD; Donald R. Branch, BS,
MT(ASCP)SBB, PhD
Intended Audience: Physicians, Scientists, Technologists
Teaching level: Intermediate to Advanced
Objectives:



Discuss how IVIg is made and how it is used in the clinic.
Discuss recent advances in mechanisms of IVIg action in autoimmune
states.
Discuss recent advances in IVIg substitutes.
Event Description: Intravenous immunoglobulin (IVIg) is produced from the
plasma of thousands of healthy blood and plasma donors. It is an expensive and
limited resource which is used to treat a wide spectrum of inflammatory diseases
and autoimmune states. Although it is considered to be generally safe, there will
always be the theoretical risk of transmission of emerging pathogens. This
session will provide an introduction to IVIG; what it is, how it is made, and how it
is used in the clinic. Recent advances in our understanding of how IVIG works to
ameliorate autoimmune disease will next be covered and finally current work on
IVIG substitutes will be presented.
(9221-TC ARS) Massive Transfusion: What Have You Done For Me Lately?
Director: Jay Raval, MD
Moderator: Darrell Triulzi, MD
Speaker: Jay Raval, MD; Mark Yazer, MD; Matthew Neal, MD
Intended Audience: Physicians, Scientists, Technologists, Nurses,
Managers/Supervisors
Teaching level: Intermediate to Advanced
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 34
Objectives:



Explain why massive transfusions are clinically important, what patient
populations may require massive transfusions, and what types of massive
transfusion protocols exist for different patients.
Describe the familiar as well as emerging evidence in massive transfusion,
the unique blood components/ratios involved, and AABB's position on
massive transfusion.
Recognize how non-trauma patients are impacted by massive transfusion
protocols and the evidence associated with this type of transfusion in this
unique patient population.
Event Description: Massive hemorrhage is an important and clinical disastrous
finding that immediately impacts the blood bank. However, multiple patient
groups, including trauma, OB/GYN, and other non-trauma patients, have been
the recipients of massive transfusion protocol activations and transfusions. This
session will illustrate the heterogeneity in massive transfusion protocols and the
evidence to support their use in various trauma and non-trauma patient
populations.
(9222-TC ARS) Hogwarts School of Antigens and Antibodies
Director/Moderator: Susan Johnson, MSTM, MT(ASCP)SBB
Speaker: Jayanna Slayten, MS, MT(ASCP)SBBcm; Monica Kalvelage,
MT(ASCP)MB, SBB; Rebecca Coward, MT(ASCP)SBB
Intended Audience: Physicians, Technologists, Managers/Supervisors
Teaching level: Basic to Intermediate
Objectives:



Discover how others approach serological testing problems.
Utilize efficient and reliable processes for problem resolution.
Learn the latest information on serological testing.
Event Description: All aboard Hogwarts Express as you enroll in AABB's
Hogwarts School of Antigens and Antibodies. Medical Laboratory
Scientists/Technologists will be challenged to demonstrate their blood bank
wizarding skills in this Harry Potter inspired series of interactive case studies.
Students will be presented with pretransfusion/prenatal test scenarios to practice
their antibody identification magic, receive problem solving approaches from
Hogwarts house faculty, and learn serologic practices from fellow blood bank
professionals as all witches and wizards are encouraged to share their spells and
potions using interactive audience response. "Graduate" from the school with
new and/or refreshed serological knowledge.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 35
(9223-TC) Organ on Demand: Where Are We With 3D Printing
Director/Moderator: Pampee Young, MD, PhD
Speaker: David Kolesky, PHD; ngela Panoskaltsis-Mortari, PhD
Intended Audience: Physicians, Scientists, Technologists, Nurses
Teaching level: Intermediate to Advanced
Objectives:



What is 3D bioprinting and its challenges.
Discuss 3D bioprinting complexities, such as the choice of materials, cell
types, growth and differentiation factors, and technical challenges related
to the sensitivities of living cells and the construction of tissues.
Addressing these complexities requires the integration of technologies
from the fields of engineering, biomaterials science, cell biology, physics
and medicine.
Application of 3D bioprinting in organ on a chip as tissue models for
research and drug discovery.
Event Description: Three-dimensional (3D) printing, is driving major innovations
in many areas, such as engineering, manufacturing, art, education and medicine.
Recent advances have enabled 3D printing of biocompatible materials, cells and
supporting components into complex 3D functional living tissues. 3D bioprinting
is being applied to regenerative medicine to address the need for tissues and
organs suitable for transplantation. Other applications include developing highthroughput 3D-bioprinted tissue models for research, drug discovery and
toxicology.
(9224-QE-IT) Clinicians' and Health Care Providers' Access to Transfusion
Medicine Information in the era of Information Technology and the Electronic
Health Record
Director/Moderator: Yunchuan Delores Mo, MD, MSc
Speaker: Gay Wehrli, MD; April Hord, BB(ASCP), BS, MS, SBB; Arnethea
Sutton, BS, MS, MT(ASCP)
Intended Audience: Physicians, Technologists, Nurses, Managers/Supervisors,
Perfusionists
Teaching level: Basic to Intermediate
Objectives:


The participant will learn steps involved to gain support for creating a
method to access transfusion medicine (TM) information in an electronic
health record (EHR).
The participant will identify the TM key points to include in this EHR
accessible location.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 36

The participant will discover the testing involved ensuring that the TM
information displays as intended in the EHR and the post implementation
monitoring involved after the go-live process.
Event Description: During this program the attendee will learn from several
transfusion services how they implemented electronically accessible transfusion
medicine information for clinicians and other health care providers. Topic will
include the why there is a need for health care providers to have easily
accessible and up to date transfusion medicine information, from patient safety to
patient blood management. The session will address: (1) the steps taken and
challenges faced when creating an accessible electronic TM site, (2) how to golive with the TM site and measure success after implementation, and (3) the
positive impact a TM site has for the blood bank and transfusion medicine
services and for the health care providers will be presented.
(9225-QE) Laboratory Developed Tests; Regulatory Update in a Growing World of
Personalized Medicine
Director/Moderator: Jed Gorlin, M.D., M.B.A.
Speaker: Kevin Halling, MD, PhD; Carla Cuthbert, Ph.D. FACMG, FCCMG
Intended Audience: Physicians, Scientists, Technologists,
Managers/Supervisors
Teaching level: Intermediate
Objectives:



Describe circumstances where use of novel unlicensed products may be
required, including the treatment of Jehovahs Witness patients.
Describe the FDA approval process for an emergency IND.
Describe limitations to the therapeutic conclusions that can be drawn from
uncontrolled usage of unlicensed products.
Event Description: This session would provide an overview of the regulatory
framework for lab-developed tests used in clinical settings and the proposed FDA
draft guidance, as well as impact to developing field of personalized medicine,
with some real-life examples/ implications.
(9226-LMT ARS) Messaging, Managing and Motivating How to Mobilize People
and Operationalize Behaviors in Times of Change
Director/Moderator: Vicki Finson, MT(ASCP)SBB
Speaker: Vicki Finson, MT(ASCP)SBB; Melinda Bryant, M-PM, PMP; Susan
Williams, MBA, CPBA
Intended Audience: Physicians, Scientists, Technologists, Nurses,
Managers/Supervisors, CEOs/CFOs
Teaching level: Basic to Intermediate
Objectives:
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 37



Provide a strategic framework of leadership practices that drive successful
navigation through organizational transitions.
Outline the predicable phases of learning, growth and change and how to
manage them.
Present managerial tools and behavioral techniques for leading and
motivating an organization through periods of ambiguity and uncertainty
(i.e., periods of transition).
Event Description: This session is an engaging and interactive experience
designed to help leaders at every level to explore what works (and what doesn't)
in leading themselves, their teams and their organizations through change. The
conversation will be founded in both theory and application, providing practical
solutions that are based on relevant examples from present-day case studies.
Participants will be invited to 1) perceive their own change experiences as both
an individual and a leader from an operational perspective, 2) explore various
tools and techniques around messaging, managing and motivating through
transition, and 3) craft a clear and intentional plan for moving forward with
impact. Note: Because great leaders of change can operate within any role of an
organization, we encourage those in non-managerial roles to attend this session
as well.
2:00 p.m. - 4:00 p.m.
(9237-TC-PBM) Clinical Practice Guidelines from the AABB: Red Blood Cell
Transfusion Thresholds and Storage
Director/Moderator: Aaron Tobian, MD, PhD
Speaker: Aaron Tobian, MD, PhD; Jeffrey Carson, MD; Nancy Heddle, MSc,
FCSMLS(D)
Intended Audience: Physicians, Scientists, Technologists, Nurses,
Managers/Supervisors, CEOs/CFOs, Perfusionists
Teaching level: Intermediate
Objectives:



Determine why AABB drafts clinical practice guidelines and how AABB
applies GRADE methodology to draft guidelines.
Evaluate the medical evidence for the optimal target hemoglobin for red blood
cell (RBC) transfusion of hospitalized hemodynamically stable adult patients
and discuss AABB's recommendation.
Evaluate the medical evidence for the length of time RBCs should be stored
prior to transfusion and discuss AABB's recommendation.
Event Description: Over 100 million units of blood are collected worldwide each year,
yet the indication for RBC transfusion and RBC storage time remains uncertain. Large
randomized clinical trials (RCTs) provide new evidence to guide RBC use. This fall the
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 38
AABB published RBC transfusion guidelines. This session will provide the background
for why AABB drafts clinical practice guidelines, describe the guideline development
process, assess the randomized trial evidence and discuss the recommendations.
2:00 p.m. - 5:30 p.m.
(9220-TC ARS) Temas de Actualidad en la Medicina Transfusional
Director: Dolores Figueroa, MT(ASCP)SBB
Moderator: Nancy Benitez, MHS (ASCP) SBB
Speaker: Marina Bueno, MLS(ASCP) CMSBBCM; Marisela Marchan, MT(ASCP)SBB;
Celina Montemayor, MD PhD; Dolores Figueroa, MT(ASCP)SBB
Intended Audience: Physicians, Technologists
Teaching level: Intermediate to Advanced
Objectives:



Revisar aplicaciones de la biologa molecular en Immunohematologia y su
utilidad para resolver casos clnicos.
Discutir las nuevas recomendaciones para el manejo de pacientes con el
Fenotipo RhD dbil.
Revisar la metodologa de algoritmos computacionales para la seleccin de
plaquetas en el paciente refractario y avances en inactivacin de patgenos en
componentes sanguneos.
Event Description: En este taller, expertos en diversas reas de la Medicina
Transfusional revisaran temas de actualidad. Se discutirn temas de biologa molecular
aplicada a los grupos sanguneos y plaquetarios, y aplicaciones de los mtodos
moleculares en el banco de sangre. Se discutir la futura aplicacin de los mtodos de
secuenciacin de nueva generacin, y la posible contribucin de los pases
latinoamericanos en el nuevo campo de Bioinformtica de clulas rojas. Adems se
revisaran avances en la inactivacin de patgenos en componentes sanguneos y el uso
de algoritmos computacionales para la seleccin de plaquetas en pacientes refractarios.
Tambin se discutirn con los participantes casos immunohematolgicos que ejemplifican
como la biologa molecular y la serologa se complementan.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 39
4:00 p.m. - 5:30 p.m.
(9227-TC) Interactive Case Studies in Perioperative Bleeding Management
Director/Moderator: Melissa Cushing, MD
Speaker: Melissa Cushing, MD; Thorsten Haas, MD; Evelyn Lockhart, MD;
James Iqbal, MD
Intended Audience: Physicians, Scientists, Technologists, Nurses,
Managers/Supervisors, Perfusionists
Teaching level: Basic to Intermediate
Objectives:



Provide brief overview of viscoelastic testing and compare the role of
viscoelastic testing in bleeding management to that of traditional
laboratory testing.
Diagnose and recommend treatment in difficult cases of ongoing or
refractory bleeding.
List scenarios where viscoelastic testing may not be useful.
Event Description: This will be an interactive case-based session on the use of
viscoelastic testing to diagnose and treat bleeding in various clinical scenarios,
including intraoperative, postoperative and intensive care settings. The speakers
will use the audience response system to engage attendees and generate
discussion. The pros and cons of viscoelastic testing will be analyzed. The risks
and benefits of various treatment approaches will be compared.
(9228-TC-CT) Choosing a Stem Cell Donor When There Are no Matched Donors
Director/Moderator: Kaaron Benson, MD
Speaker: Ernesto Ayala, MD; Taiga Nishihori, MD
Intended Audience: Physicians, Scientists, Technologists, Nurses
Teaching level: Intermediate to Advanced
Objectives:



To identify the options available to hematopoietic stem cell transplant (HSCT)
patients who do not have an HLA-matched donor
To briefly describe the process for haploidentical donor HSCT and patient
outcomes
To briefly describe the process for cord blood and mismatched unrelated
donor HSCT and patient outcomes
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 40
Event Description: Patients with life-threatening hematologic malignancies may be
cured with hematopoietic stem cell transplant (HSCT). The best outcomes are with
perfectly HLA-matched donors but about 25% of whites and up to 80% of other racial
and ethnic groups have no HLA-A, HLA-B, HLA-C, HLA-DRB1 identical donor.
Alternatives to full HLA-matched donor HSCT include use of haploidentical donors, cord
blood and mismatched unrelated donors (MMUD). Haploidentical donors are available
for most patients as they include all first-degree relatives, e.g., parents, children and
50% of full siblings. As matching requirements are less stringent for cord blood, many
patients are eligible but interest in this donor source has waned. MMUD are also
commonly available for patients in need. This program will review these options and
describe the process for each of the three types of alternatives to full HLA-matched
HSCT and review patient outcomes to date.
(9229-TC-RC-HEM) Hemovigilance for Blood Collectors
Director: Barbee Whitaker, PhD
Moderator: Kevin Land, MD
Speaker: Mary Townsend, MD; Barbee Whitaker, PhD; Kevin Land, MD; Mark
Fung, MD, PHD; James Stubbs, MD
Intended Audience: Physicians, Nurses, Managers/Supervisors, Perfusionists
Teaching level: Intermediate
Objectives:



To describe trends in Donor Hemovigilance through presentation of 20122014 Donor Hemovigilance data reported to AABB.
To demonstrate the harmonized adverse reaction form for hospitals to use
in reporting reactions to blood centers.
To report on the validation of the internationally harmonized definitions for
blood donor reactions.
Event Description: This session will address hemovigilance for blood collectors.
Trends in blood donor hemovigilance will be discussed. The role of the blood
collectors in monitoring and encouraging transfusion reaction reporting through
use of a common reaction reporting form will be reviewed. Internationally
harmonized donor adverse reaction definitions and their validation will be
described.
(9230-QE) Crucial Conversations: Strategies for Maintaining Professionalism and
Enhancing Communication Between the Transfusion Service and Clinical Teams
Director/Moderator: Theresa Nester, MD
Moderator: Deborah Sesok-Pizzini, MD, MBA
Speaker: Nancy Dunbar, MD; Mark-Alan Pizzini, MD
Intended Audience: Physicians, Nurses
Teaching level: Basic to Intermediate
Objectives:
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 41



Review concepts of professionalism and how to recognize when you or others
are "out of role."
Discuss educational programs that engage pathology residents to have a
visible presence in the hospital.
Generate ideas of enhancing communication between the transfusion service
and clinical teams using blood.
Event Description: This session is intended to share ideas for curriculum
development, both for pathology residents and for other residents likely to use blood
as part of their daily work. Time spent sharing knowledge during the day with clinical
colleagues can make those difficult 2am conversations much easier, or even
eliminate those conversations that arise from a knowledge gap. When these difficult
conversations do arise, it is important to maintain professionalism. This session will
highlight strategies for helping trainees to maintain focus on the patient in a
professional way, and for educating clinicians to understand common goals related
to optimal transfusion support.
(9231-QE ARS) Test Your Blood Bank Knowledge
Director/Moderator: Jayanna Slayten, MS, MT(ASCP)SBBcm
Speaker: Karen Byrne, MDE, MT(ASCP)SBB; LeeAnn Walker, MEd,
MT(ASCP)SBB; Lorraine Blagg, MA, MLS(ASCP)SBB; Stacey Alvey, MEd,
MT(ASCP)SBB; Kate Hernandez, MT(ASCP)SBB
Intended Audience: Physicians, Scientists, Technologists,
Managers/Supervisors
Teaching level: Intermediate to Advanced
Objectives:



Review basic to advanced knowledge in blood banking/transfusion
medicine.
Using the ASCP SBB/BB categories and content outline as the basis,
challenge participants to recall technical, scientific and management
information.
Provide entertainment while allowing participants to assess their
knowledge.
Event Description: Using a modified "Jeopardy" game show format and in the
spirit of friendly competition, multiple-choice questions will be presented to the
audience in categories corresponding to the ASCP SBB and BB exam content
outlines. Responses will be tallied by audience response technology and final
scores will be announced to the competing teams.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 42
(9232-LMT ARS) Voice of the Customer: Can You Hear Me Now?
Director/Moderator: Jeffrey Schuh, BA
Speaker: Jeffrey Schuh, BA; Jennifer Sanders
Intended Audience: Managers/Supervisors, CEOs/CFOs
Teaching level: Basic to Intermediate
Objectives:



Introduce Voice of the Customer and its importance in business decision
making.
Discuss BSIs incorporation of VOC when interacting with outside
customers.
Demonstrate the internal use of VOC when deciding on the next
generation of Self Contained Units (buses, coaches, trucks).
Event Description: Voice of the Customer (VOC)is a tool used by businesses to
understand and anticipate the needs and wants of their customers. Realizing that
VOC is more than just annual surveys, Blood Systems Blood Center Division
chartered and completed a project to expand the number, type and analysis of
information gathered when talking to our various external customers. In addition,
VOC was used internally as an important part of a new vehicle design and
selection process.
(020A) Scientific Oral Abstract Session: Recipient Non-Infectious Adverse Events
(020B) Scientific Oral Abstract Session: Transfusion Practice I
(020C) Scientific Oral Abstract Session: RBC Molecular Testing and Genetics
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 43
6:00 p.m. - 7:30 p.m.
----------------------------Research and Progress (RAP) Sessions
The RAP sessions focus on new developments, rather than review general
topics, and will convene experts in each area under discussion. Formal
presentations are limited, emphasis will be on discussion and sharing of
experiences among all attendees. The sessions will be held simultaneously. All
RAP sessions are available for CME credits. Beverages and light hors d’oeuvres
will be available for attendees at these sessions.
----------------------------(9233-TC-CT) Research and Progress (RAP) Sessions: New Horizons for Graftversus-Host Disease
Director: Jay Raval, MD
Check back for topic and a detailed description.
(9234-TC) Research and Progress (RAP) Sessions: Inside Job or Outsourced —
Transfusion Service Operational Options
Check back for topic and a detailed description.
(9235-TC) Research and Progress (RAP) Sessions: Little People with Low
Platelets: Which Neonates Benefit from Prophylactic Platelet Transfusions?
Check back for topic and a detailed description.
(9236-TC Research and Progress (RAP) Sessions: Is it Time to Revisit the
Concept of ABO "Universal Donor" Red Cells and Plasma?
Check back for topic and a detailed description.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 44
MONDAY, OCTOBER 24, 2016
8:30 a.m. - 10:00 a.m.
(9302-TC-CT) Best Practices from the Cellular Therapy Quality Ops Subsection
Director/Moderator: Kathleen Fortune, MT(ASCP)
Speaker: Shilpa Choudhari, MS, CQA (ASQ); Itzia Iglesias, MS
Intended Audience: Physicians, Technologists, Managers/Supervisors
Teaching level: Basic to Intermediate
Objectives:


Showcase time tested practices in Quality operations.
Present practical and useful solutions to quality problems in cellular
therapy.
Event Description: Best practices in a variety of areas will be presented. These
best practices have been chosen by the leadership of the cellular therapy quality
operations subcommittee from presentations given at the subcommittee monthly
meetings. Audience participation will be encouraged so come prepared with your
own "best practices."
(9303-QE-CT) CLIA for CT Labs: What Applies, When and Who is Responsible
Director/Moderator: Lisa Phillips Johnson, MT(ASCP)SBB, CQA, CMQ/OE,
RAC
Speaker: Lisa Phillips Johnson, MT(ASCP)SBB, CQA, CMQ/OE, RAC; Lizette
Caballero, MLS (ASCP)CM; Olive Sturtevant, MHP, MT(ASCP)SBB, SLS,
CQA(ASQ)
Intended Audience: Physicians, Technologists, Managers/Supervisors
Teaching level: Basic to Intermediate
Objectives:



Provide an overview of CLIA regulations / requirements, specific to CT
labs.
Explain proficiency testing, competency assessments and other
responsibilities for CT labs.
Provide some examples of lab processes in place to support these
requirements.
Event Description: This session would provide an overview of CLIA
requirements and resources available for CT labs, explaining clinical use of tests
vs product testing. An overview of the need for proficiency testing, competency
assessments and other aspects of quality system requirements for labs would be
discussed, as well as staffing qualifications and responsibilities. Speakers will
include examples of application to round out this session.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 45
(9304-QE) Blood Bank Proficiency, Competency and QC: A Practical Approach to
CLIA Requirements and AABB, CAP and Joint Commission Expectations
Director: Dickie Nichols, MT(ASCP)SBB
Moderator: Dawn Rumsey, ART(CSMLS) BB(ASCP)
Speaker: Denise Driscoll, MS, MT(ASCP)SBB; Anne Chenoweth, MBA,
MT(ASCP)CM, CQA(ASQ); Heather McGann, MT(ASCP) SBB; Stacy Olea,
MT(ASCP), FACHE
Intended Audience: Technologists, Managers/Supervisors
Teaching level: Basic to Intermediate
Objectives:



Discuss the relationships between the laboratory, CLIA and deemed
status Accrediting Organizations and Bodies.
Clarify requirements for IQCP.
Describe and compare the criteria for Competency, Proficiency and QC of
three of the deemed status. Accrediting Organizations based upon CLIA
requirements.
Event Description: Illustrate methods used by a transfusion service for fulfilling
these requirements.
(9305-LMT) Disruptive Forces and Critical Success Factors in Healthcare
Director: Jean Stanley, MBA, MT(ASCP)SBB, CMQ/OE(ASQ)
Moderator: JoAnn Hegarty, MT(ASCP)SBB, MT(ASCP)SBB
Speaker: Robert Michel; Rick Panning, MBA, MLS(ASCP)CM
Intended Audience: Physicians, Technologists, Nurses, Managers/Supervisors,
CEOs/CFOs
Teaching level: Intermediate to Advanced
Objectives:



Explain the ten disruptive forces that are impacting healthcare today.
Recognize how critical success factors rely on a commitment to and
capacity for reinvention and innovation.
Identify critical success factors that blood centers should consider in
leveraging their relationship with hospitals.
Event Description: Disruptive forces in healthcare provide challenges to both
hospitals and blood centers. Healthcare leaders will need to address these forces
in their strategies if they intend to realize sustainability and continue growth in a
significantly changing marketplace. Hospital and blood center leadership also
need to recognize the importance of critical success factors which include issues
vital to an organization's current operating activities, and require a commitment
and capacity to provide special and continual attention to bring about future
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 46
success. These critical success factors are especially important as blood centers
struggle to maintain a balance between assisting hospitals with better patient
blood utilization and financial sustainability. Come learn about these disruptive
forces and how the relationship between hospitals and blood centers can be
leveraged to meet these challenges.
(9306-LMT) Staffing to Workload
Director/Moderator: Karafa Badjie, MS, MLS(ASCP)SBB, BMLSc
Speaker: Karafa Badjie, MS, MLS(ASCP)SBB, BMLSc; Theresa Downs,
MT(ASCP)SBB, CQA(ASQ); Joy Gomez; Raymond Frick
Intended Audience: Physicians, Scientists, Technologists, Nurses,
Managers/Supervisors, CEOs/CFOs, Perfusionists
Teaching level: Intermediate
Objectives:



Discuss data driven methods to capture workload.
Develop staffing models to align laboratory staffing with workload demand.
Improve FTE productivity by aligning staffing with the workload demand to
reduce turnaround times.
Event Description: The interactive workshop will focus on a data driven and
systematic approach to understand demand, identify idle time, and optimize work
schedules. The workshop will examine the different variations that exist when
performing staffing to workload analysis. Case studies will be utilized to generate
ideas. Tools will be provided to complete the analysis.
(030A) Scientific Oral Abstract Plenary Session
(9332-S-HEM) Results from the 2015 Blood Surveys
Director: Barbee Whitaker, PhD
Moderator: Steve Kleinman, MD
Speaker: Barbee Whitaker, PhD; Kathryn Haass, MPH, CPH, MT(AAB),
BB(ASCP)M
Intended Audience: Physicians, Scientists, Technologists, Managers/Supervisors,
CEOs/CFOs
Teaching level: Intermediate
Objectives:



Review the trends in blood collection and utilization in the United States and
among AABB members.
Describe differences in sampling and survey methodologies of national and
member surveys which may impact collection and utilization estimates.
Compare results to 2013 surveys.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 47
Event Description: This session will include presentations from the surveys
designed to estimate blood collection and utilization in the United States form
2015 data. AABB will present findings from the 2015-2015 AABB Blood
Collection and Utilization Survey of member facilities. The CDC will present
findings from the 2015 HHS National Blood Collection and Utilization Survey.
10:30 a.m. - 12:00 p.m.
(9308-S) Does Blood Transfusion Prevent Aging?
Director/Moderator: Jose Cancelas, MD, PhD
Speaker: Hartmut Geiger, PhD; James Ferrara, MD
Intended Audience: Physicians, Scientists, Technologists, Nurses
Teaching level: Intermediate to Advanced
Objectives:

Learn how stem cell aging is affecting the basic biology of immune
reconstitution and the incidence, prevalence and prognosis of graftversus-host disease of allogeneic stem cell transplantation recipients.
Event Description: Stem cell aging impacts the clinical outcome of stem cell
transplantation by reduced potency, myeloid differentiation bias, decreased
ability to support lymphopoiesis and reduced immunocompetence. Host aging is
impacting the incidence and severity of graft-versus-host disease. This session
will provide an update on recent findings in the biology and treatment of agingrelated complications in the context of stem cell transplantation.
(9309-S) The Role of Platelet and Coagulation Activation in Sickle Cell Disease
AABB/ASH Joint Program
Director/Moderator: Patricia Shi, MD
Speaker: Ted Wun, MD; Nigel Key, MD
Intended Audience: Physicians, Scientists, Nurses
Teaching level: Intermediate to Advanced
Objectives:



Discuss the pathophysiology and role of platelet and coagulation
activation in sickle cell disease.
Demonstrate understanding of the role of cell-derived microparticles in
vaso-occlusion and allo-immunization.
Critically evaluate ongoing and potential clinical studies in these areas.
Event Description: This session will review the pathophysiology and role of
platelet activation in sickle cell vaso-occlusion in light of the pasugrel trial, the
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 48
current understanding of the pathophysiology and role of coagulation activation,
and the interplay of the two with heme and cell-derived microparticles. The
potential benefit of further clnical studies in these areas will be discussed.
(9310-S) The ABCs of transfusion-related hypotension: Anaphylaxis, Bradykinin,
and Contamination
Director/Moderator: Aaron Tobian, MD, PhD
Speaker: William Savage, MD, PhD; Monica Pagano; Richard Benjamin, MD
Intended Audience: Physicians, Scientists, Technologists, Nurses
Teaching level: Intermediate
Objectives:



Review the pathophysiology, epidemiology, and treatment of hypotensive
transfusion reactions.
Review the pathophysiology, epidemiology, and treatment of hypotension
in septic transfusion reactions.
Review the pathophysiology, epidemiology, and treatment of hypotension
in anaphylactic transfusion reactions.
Event Description: Hypotension is an uncommon, but life-threatening
complication of transfusion that requires emergent treatment. This course will
review the differential diagnosis of hypotension in the setting of transfusion and
describe in depth the distinct pathophysiology of hypotension in three unrelated
transfusion reactions. Hypotensive, septic, and anaphylactic reactions can share
hypotension as a presenting sign, although the pathways that lead to
hypotension are largely distinct. An understanding of the distinct pathways
involved will illustrate why risk factors and treatments differ among these causes
of hypotension.
(9311-TC) Ask the Standards
Director/Moderator: David McKenna, MD
Speaker: Patrick Ooley, MS, MT(ASCP), CQA(ASQ)CMQ/OE; Mary Berg, MD;
Richard Haspel, MD, PhD
Intended Audience: Physicians, Scientists, Technologists
Teaching level: Intermediate to Advanced
Event Description: Presentations will be given by standard subcommittee chairs
regarding standards in his or her discipline. Questions for the discussion are to
be submitted before the scheduled session via the AABB website starting late
August and during the session.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 49
(9312-TC) Clinical Challenges of Chimerism
Director: Nicole Draper, MD
Moderator: Mary Berg, MD
Speaker: Nicole Draper, MD; Joel Kniep, MD; Shalini Shenoy, MD
Intended Audience: Physicians, Scientists, Technologists,
Managers/Supervisors
Teaching level: Intermediate to Advanced
Objectives:



Discuss causes of congenital and acquired macro- and microchimerism in
humans.
Apply concepts of chimerism to make clinical diagnoses.
Use information about chimerism to predict clinical outcomes and choose
between treatment options.
Event Description: With the increasing frequency of organ and hematopoietic
progenitor cell transplantation, the population of chimeric individuals is also
rising. An understanding of the causes of chimerism and the clinical implications
for transplantation and transfusion is needed to properly care for these chimeric
patients. Chimerism poses a special challenge for transfusion of blood products
because it can lead to typing discrepancies and unexpected antibodies.
Additionally, blood products need to be chosen based on compatibility with the
host and the graft. Congenital chimerism is often discovered due to abnormalities
on ABO typing or HLA typing as part of the transplantation process. Example
cases will be used to illustrate concepts such as congenital chimerism identified
by HLA typing, the importance of chimerism in HSCT for sickle cell disease,
transfusion in ABO and Rh mismatched HSCT, and passenger lymphocyte
syndrome after solid organ transplantation.
(9313-TC) Roundtable Discussions for Molecular Immunohematology
Professionals
Director: Greg Denomme, PhD
Moderator: Bill Flegel, MD
Speaker: Maryse St-Louis, PhD; Dan Waxman, MD; Christopher Tormey, MD;
Lilian Castilho, PhD; Silvano Wendel, MD, PhD; Gary Stack, MD, PhD; Margaret
Keller, PhD; William Lane, MD, PhD; Ellen Klapper, MD; Christof Weinstock, MD;
France Pirenne, MD, PhD; Qing Chen, MD; Bill Flegel, MD
Intended Audience: Physicians, Scientists, Technologists,
Managers/Supervisors, CEOs/CFOs
Teaching level: Basic to Intermediate
Objectives:

Network with laboratory and clinical professionals who have an interest in
molecular immunohematology and blood group genetics.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 50


Compare and contrast challenging or controversial concepts in
immunohematology.
Meet and interact with world leaders in molecular immunohematology.
Event Description: The molecular immunohematology roundtable workshop
returns for another year! This session has resulted in three publications in
previous years that summarized the comments and opinions of you, the
immunohematology professional. Modeled on a speed dating format, the event
will consist of small group discussion led by "chaperones", who act as scribes for
the participants. The year's session will consist of thesis statements for groups of
8 to 10 participants who will compare and contrast their ideas and opinions.
Chaperones will move from one table to another to facilitate discussion. At the
conclusion, the chaperons give a short summary. For the inexperienced
immunohematologist, it is an opportunity to become familiar with a new field and
to forge professional friendships. For the seasoned professional, it's an
opportunity to share experiences and swap ideas. Join us and look for your
collective opinions to appear in print.
(9314-TC-CT) Adverse Events and Specific Stem Cell Products
Director/Moderator: Jay Raval, MD
Speaker: Laura Cooling, MD, MS; Rebecca Haley, MD; David Maloney, MD,
PhD
Intended Audience: Physicians, Scientists, Technologists, Nurses,
Managers/Supervisors
Teaching level: Intermediate to Advanced
Objectives:



Describe the unique complications that can occur with the infusion of
HPC,Apheresis and HPC,Marrow products and how to manage/prevent
them.
Describe the unique complications that can occur with the infusion of
HPC,Cord products and how to manage/prevent them.
Recognize the unique complications that can occur with the infusion of
CAR T cells and how to manage/prevent them.
Event Description: It is important to recognize that unique complications exist
with the infusion of unique stem cell products. With the increased use of HPC,
Cord products, increased ABO-incompatible HPC, Marrow products,
cryopreserved HPC, Apheresis products, and CAR T cell therapies, increased
numbers of complications are being observed that are associated with each of
these unique products, including (but not limited to) stunned heart syndrome,
hemolytic reactions, granulocyte/DMSO toxicities, and cytokine release
syndrome, respectively. In this session, the goal is to characterize and explain
why certain complications occur with unique stem cell products, how these
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 51
complications can be managed/prevented, and how tracking/recording/reporting
of these complications is critical to product improvement and recipient safety.
(9315-TC) Interference with Blood Compatibility Testing by Monoclonal Antibody
Therapy — What, Why and How to Resolve
Director/Moderator: Joseph Schwartz, MD, MPH
Speaker: Richard Kaufman, MD; Jacob Laubach, MD; Karen De Vooght, PhD
Intended Audience: Physicians, Scientists, Technologists,
Managers/Supervisors
Teaching level: Basic to Intermediate
Objectives:



Outline the preclinical and clinical data for monoclonal antibody therapy,
specifically daratutumab (DARA) and other anti-CD38 antibodies, and the
potential therapeutic applications of anti-CD38 beyond multiple myeloma.
Review the blood banking testing and the interference observed when
daratutumab (DARA) is being used as a therapeutic modality and currently
existing techniques to resolve it such as using DTT-treated red blood cells
or genotyping.
Understand the potential techniques that are in development in order to
resolve the interference — e.g. using anti-idiotype antibodies to neutralize
anti-CD38 in vitro.
Event Description: Monoclonal antibodies are increasingly being used in the
care of patients with a variety of conditions including malignancy, infection and
inflammatory diseases. The interference of monoclonal antibodies with clinical
laboratory tests is an emerging concern that requires both recognition and the
development of appropriate solutions. Daratumumab (DARA), a novel anti-CD38
monoclonal antibody is being developed to treat patients with multiple myeloma.
While in clinical trials, its use resulted in interference with routine blood banking
compatibility testing which might preclude the correct identification of irregular
blood group antibodies for patients requiring blood transfusion. Therefore,
developing solutions to overcome this interference is critical for patient safety.
This session will provide an introduction to monoclonal antibody therapy, with a
focus on DARA and other anti-CD38 antibodies. The potential therapeutic
applications of anti-CD38 in multiple myeloma and beyond will be discussed. The
blood bank testing affected by the DARA interference will be described, along
with possible solutions to overcome the interference using currently available
techniques. Finally, a review of potential future techniques to resolve the
interference, such as using anti-idiotype antibodies to neutralize anti-CD38 in
vitro, will be provided.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 52
(9316-QE) What's Wrong With This Picture...Auditing and Finding Quality
Problems in the Transfusion Service
Director/Moderator: Regina Castor, BS, MT(ASCP)SBB
Speaker: Rosemary Steuber, MT, SBB(ASCP)
Intended Audience: Technologists, Managers/Supervisors
Teaching level: Basic to Intermediate
Objectives:



Describe items to consider including in auditing the Transfusion Service.
Understand examples of errors that can be uncovered in the auditing
process.
Learn strategies for improving the auditing process.
Event Description: This session will provide examples of items uncovered
during auditing processes. Examples of "What can go wrong" will be shared.
Through these examples, strategies for improving auditing and improving quality
processes will be shared. Examples will include equipment audits, instrument
and reagent audits, and form design among others. By sharing some of the
pitfalls experienced by peers, learn how to avoid the mistakes of others.
(9317-QE) Revision to 21 CFR Part 600 Impact to Donors and Blood Center
combined w/ Implementing the Final Rule
Director/Moderator: Roxanne Tata, MT(ASCP)SBB, CQA(ASQ)
Speaker: Galen Kline, BS, CLSSBB; Elizabeth DeAngelo; Chelsea Sheppard,
MD
Intended Audience: Physicians, Scientists, Nurses, Managers/Supervisors
Teaching level: Intermediate
Objectives:




Understand the changes required with the implementation of the Final
Rule for 21CFR, Part 600 requirements for blood and blood components
for future manufacturing use.
Understand the changes related to donor deferral record keeping, donor
suitable changes and review of the data since implementation of changes.
Review and understand the role and responsibility of the blood center
physician.
Review the changes related to testing frequency for future flexibility.
Event Description: The implementation of the long awaited rule affecting
21CFR Part 600, Requirement for Blood and Blood Components Intended for
Transfusion or for Further Manufacturing Use (Final Rule) has had significant
impact on operations and blood centers. This program will review changes, show
how blood centers have implemented changes and review current data from the
implemented changes.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 53
(9318-LMT) Bleeding Edge Information Solutions for Transfusion Medicine
Director: Ronald Hardin
Moderator: Liz Carter, MT(ASCP)SBB, CQA
Speaker: Martin Morey; Ronald Hardin; Kevin Harrington
Intended Audience: CEOs/CFOs
Teaching level: Intermediate to Advanced
Objectives:



Identify what capabilities health care organizations need to build digital
leadership.
Provide a blueprint for project planning and execution of a data management
strategy.
Discuss actionable insights to the software tools evaluation & selection
process.
Event Description: This session provides practical solutions and actionable advice for
blood bank executives. In today’s healthcare environment organizations will need a
robust digital strategy to remain competitive. To reach this level you need an approach
to data management that empowers people to build the analytics they need to improve
their business insights. Industry professionals will share challenges and successes in
the journey to creating an enterprise data warehouse and big data solutions. Time will
be provided at the end of presentation to ask questions.
(9319-LMT) Organizational Integration: Successes, Challenges and Lesson's
Learned
Director/Moderator: Mary Lieb, BS, MT(ASCP)SBB, CQA(ASQ)
Speaker: Tammy Croak-Wilson, MT(ASCP)SBB; Vicki Finson, MT(ASCP)SBB;
Alexander Socarras
Intended Audience: Physicians, Scientists, Technologists, Nurses,
Managers/Supervisors, CEOs/CFOs, Perfusionists
Teaching level: Intermediate to Advanced
Objectives:



Describe the similarities and differences presented in each approach
taken for effective integration in mergers and acquisitions.
Identify the successes and challenges encountered in each approach
presented for integration in newly aligned organizations.
Discuss the lessons learned identified in each of the presentations that will
allow for better organizational integration.
Event Description: Mergers and acquisitions are an industry trend creating a
paradigm shift in health care delivery. There are many strategies and activities to
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 54
achieve successful integration of newly aligned organizations. Three scenarios
will be presented from the vendor, hospital and blood center perspective for
organizations that are currently involved in organizational integration. Similarities
and differences in philosophy, approach and implementation of integration
activities will be discussed. Successes and challenges including "lessons
learned" will be addressed in each presentation. An opportunity for questions and
answers will be provided at the conclusion of the presentation.
2:00 p.m. - 3:30 p.m.
(9321-TC) Clinical Manifestations, Etiology, and Pathogenesis of Hyperhemolysis:
Time to Start a Registry!
Director: Karina Yazdanbakhsh, PhD
Moderator: France Pirenne, MD, PhD
Speaker: Karen King, MD; France Pirenne, MD, PhD; Sally Campbell-Lee, MD
Intended Audience: Physicians, Scientists, Technologists, Nurses,
Managers/Supervisors, CEOs/CFOs, Perfusionists
Teaching level: Intermediate
Objectives:



To describe clinical features of hyperhemolyis in patients with sickle cell
disease and its management.
To describe potential risk factors associated with hyperhemolyis and new
treatment options.
To discuss a proposal to build an international, multi-center
Hyperhemolysis Registry.
Event Description: Patients with sickle cell disease receiving transfusions can
experience hyperhemolysis, a life-threatening poorly understood phenomena in
which the transfused and the patient's own red blood cells (RBCs) are destroyed.
This type of hemolytic reaction is unpredictable and potentially under-recognized
because its clinical presentation may resemble pain crisis. Due to the small
numbers of patients that are encountered at individual hospitals and centers, the
prevalence of hyperhemolysis amongst SCD remains imprecise. Development of
new or reactivation of alloantibodies together with clinically relevant
autoantibodies may explain hyperhemolysis trigger in some cases; however,
hyperhemolysis can occur in the absence of detectable alloantibodies or
autoantibodies; yet little is known about the etiology of hyperhemolysis in such
cases or the clinical and laboratory features that may distinguish hyperhemolysis
subgroups. Studies to elucidate their underlying mechanism of hyperhemolysis,
are critical for SCD patient care. In this session, Dr. Karen King will review some
of the clinical features of hyperhemolyis and its management. Dr. Pirenne will
describe potential risk factors associated with hyperhemolyis and new treatment
options. Dr. Sally Campbell-Lee will discuss a proposal to build an international,
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 55
multi-center Hyperhemolysis Registry as a first step to assess prevalence,
clinical and laboratory features of hyperhemolysis.
(9322-TC) Highlights from the American Society for Apheresis (ASFA) Guidelines
on the Use of Therapeutic Apheresis in Clinical Practice, 7th Edition AABB/ASFA
Joint Program
Director: Jill Adamski, MD, PhD
Moderator: Lance Williams, MD
Speaker: Nicole Aqui, MD; Joseph Schwartz, MD, MPH; Anand Padmanabhan,
MD, PhD, MA, Tina Ipe, MD, PhD
Intended Audience: Physicians, Technologists, Nurses, Managers/Supervisors
Teaching level: Basic to Intermediate
Objectives:



Describe the history and methodologies used to create the 7th edition of
apheresis guidelines.
Review critical updates in for previously published clinical indication fact
sheets.
Introduce fact sheets for the therapeutic apheresis indications that are
appearing for the first time in the 7th edition.
Event Description: The ASFA Journal of Clinical Apheresis (JCA) Special Issue
Writing Committee performs a rigorous review of the published literature relating
to therapeutic apheresis in the interval between the JCA apheresis guidelines
special issues. Fact sheets are updated and new clinical indications are
considered. Each indication is assigned a treatment category (I-V) and a strength
of recommendation based on the GRADE system. The newest edition (7th) of the
JCA apheresis guidelines will be presented during this session. Speakers will
discuss methodologies used to classify clinical indications, the processes by
which consensus categorizations/GRADE are assigned, important updates and
changes from the 6th edition, and introduce fact sheets for new clinical
indications.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 56
(9323-TC-CT) AABB/TERMIS-Americas Joint Program: Regenerative Medicine
Therapies for Wounded Soldiers
Director: James Yoo, MD, PhD
Moderator: Anthony Ratcliffe, PhD
Speaker: Kacey Marra, PhD; Simon Young, DDS, MD, PhD; James Yoo, MD,
PhD
Intended Audience: Physicians, Scientists, Technologists, Nurses,
Managers/Supervisors, CEOs/CFOs
Teaching level: Intermediate
Objectives:



Discuss approaches for translational applications in regenerative
medicine.
Describe unmet clinical needs and how regenerative medicine therapies
are applied.
Discuss clinical translation of regenerative medicine technologies for
military.
Event Description: Regenerative medicine focuses on the development of new
approaches to repairing cells, tissues and organs for clinical applications. This
session will provide insights into the rapidly evolving field of regenerative
medicine. This session will highlight technologies that are being developed to
help wounded soldiers with battlefield injuries.
(9324-TC) Real World Application of Next Generation Sequencing in Transfusion
Medicine
Director/Moderator: Connie Westhoff, PHD, SBB
Speaker: William Lane, MD, PhD; Stella Chou, MD; Connie Westhoff, PHD, SBB
Intended Audience: Physicians, Scientists, Technologists, Nurses,
Managers/Supervisors, CEOs/CFOs
Teaching level:
Objectives:



To discuss the process used to determine red cell and platelet antigens
from whole genome sequence.
To present data comparing SNP testing to whole exome sequencing for
RH genotyping.
To stimulate discussion on how the use of genomic information might
change our approach to pre-transfusion testing.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 57
Event Description: Typing for red cell and platelet antigens by targeting single
nucleotide polymorphisms (SNPs) is now commonplace, but there are limitations
especially for ABO and RH. Next generation sequencing is rapidly being applied
in many areas of medicine. Individuals with hematologic malignancies and
chronic illness may soon get routine whole genome sequencing for diagnosis or
treatment. This data can be used in transfusion medicine. The speakers, who
have published in this rapidly expanding field, will discuss their experience
applying whole genome and exome sequencing approaches to determine blood
group antigen expression and envision the future of pretransfusion testing in the
era of genomics.
(9325-QE) Creating a Successful Training Program for Today's Blood Bank
Learner: Does it Have to be Electronic for Them to Pay Attention?
Director: Karen Byrne, MDE, MT(ASCP)SBB
Moderator: J. Wade Atkins, CQA(ASQ), MS, MT(ASCP)SBB
Speaker: April Hord, BB(ASCP), BS, MS, SBB; Regina Castor, BS,
MT(ASCP)SBB; Deirdre Parson, MS, MT(ASCP)SBB
Intended Audience: Physicians, Technologists, Nurses, Managers/Supervisors
Teaching level: Basic to Intermediate
Objectives:



Identify content development and requirements that need to be included in
a training program to increase understanding and compliance.
Review new insights into how to deliver effective training for today's
learner.
Summarize tools to measure the effectiveness of learning requirements.
Event Description: Teaching today is very different from five to ten years ago.
While the basis of content development may not change, how does one capture
and hold the attention of today's learner? Are the social media tools of today a
booster or a hindrance for today's instructor? Are lessons taught today effective
for ensuring compliance with blood bank and cellular therapy regulations and
safety requirements? The speakers in the session will answer these questions
and share methods for successful training programs for today's learner.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 58
(9326-QE-CT) Aligning Hospital Strategy and Quality Initiatives in the Stem Cell
Lab
Director/Moderator: Deborah Sesok-Pizzini, MD, MBA
Speaker: Yongping Wang, MD, PhD; Kathleen Fortune, MT(ASCP)
Intended Audience: Physicians, Scientists, Technologists, Nurses,
Managers/Supervisors, CEOs/CFOs
Teaching level: Intermediate
Objectives:



To describe methods for aligning hospital strategy with quality initiatives in
the stem cell lab.
To introduce new electronic methods for tracking and trending stem cell
quality.
To learn basic quality tools for reporting and reviewing quality in the stem
cell lab.
Event Description: Hospital strategic planning impacts decision making in the
laboratory with regards to goal setting and program development. This also
impacts stem cell quality initiatives which need to incorporate newer quality
metrics and methods for monitoring these goals. In this session, we will describe
examples to align strategic goals with quality metrics and review methods and
tools used to monitor these metrics.
(030B) Scientific Oral Abstract Session: Pediatric Transfusion Medicine
(030C) Scientific Oral Abstract Session: Transfusion Practice II
(030D) Scientific Oral Abstract Session: Components and Component
Processing I
(030E) Administrative Oral Abstract Session: Blood Management
(030F) Administrative Oral Abstract: Management, Finance and General Marketing
(030G) Administrative Oral Abstract Session: Collections and Product
Manufacturing
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 59
4:30 p.m. - 6:00 p.m.
(9327-TC-IT) iTransfusion: Using Informatics to Deliver Safer, Personalized
Transfusion Therapy
Director: Richard Kaufman, MD
Moderator: Meghan Delaney, DO, MPH
Speaker: Eric Krieg; Dee Townsend-McCall, RN, BSN; Lawrence Goodnough,
MD; Michael Murphy, MD, FRCP, FRCPATH, FFPATH (M.)
Intended Audience: Physicians, Scientists, Technologists, Nurses,
Managers/Supervisors
Teaching level: Intermediate to Advanced
Objectives:



Assess the latest informatics tools for improving transfusion safety for
blood ordering and nursing practice.
Evaluate the resources and requirements to use informatics to improve
laboratory practice in the transfusion service.
Evaluate the impact of electronic decision support for transfusion on both
clinical outcomes and blood use.
Event Description: In this program, a broad multidisciplinary team of speakers
(laboratory, nursing, and medical) will describe how novel information technology
(IT) solutions have been employed to advance all aspects of transfusion care-from the blood bank to the bedside--through electronic process and decision
support tools.
(9328-TC-CT) Solve It! Scenarios in Cellular Therapy
Director/Moderator: Michele Sugrue, MS, MT(ASCP)SBB
Speaker: Michele Sugrue, MS, MT(ASCP)SBB
Intended Audience: Physicians, Scientists, Technologists, Nurses,
Managers/Supervisors
Teaching level: Intermediate
Objectives:



Discuss creative solutions to manage common technical, clinical, and
administrative challenges using case scenario approach.
Review regulatory requirements and accreditation standards while
developing strategies to resolve common hurdles in daily practices.
Network with cellular therapy colleagues and experts in the field in a
congenial and informal atmosphere.
Event Description: With overwhelming enthusiasm, Solve It! Scenarios in
Cellular Therapy returns to the AABB Annual Meeting, offering an interactive and
productive program for Cellular Therapy Professionals. Recognizable case
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 60
scenarios will be presented in small groups followed by discussions and
generation of potential resolutions. This program will allow attendees to select
topics of particular interest and rotate through multiple scenario case
presentations. The atmosphere is congenial and informal, and no preparation is
needed! Join us for lively interactions and networking with fellow Cellular Therapy
colleagues.
(9329-TC) Personalized Transfusion Medicine: RH Genotype Matching
Director: Margaret Keller, PhD
Moderator: Sandra Nance, MS, MT(ASCP)SBB
Speaker: Thierry Peyrard, PhD, PharmD, EurClinChem; Lilian Castilho, PhD;
Margaret Keller, PhD; Greg Denomme, PhD
Intended Audience: Physicians, Scientists, Technologists
Teaching level: Intermediate to Advanced
Objectives:



Introduce the concept of RH genetic variation and expression of variant
antigens and that multiple RHCE alleles may appear to have the same
predicted phenotype.
Present data on one or more RH alleles recently shown to express partial
antigens and on their ability to identify donors to match patients with
alloantibodies; some of the speakers will present alloimmunization data on
patients receiving and not receiving RH-matched blood.
Discuss the practical value of RHCE genotyping, how this information can
be communicated to clinicians, and transfusion services staff and how the
information can be used to identify potentially genocompatible donors.
Event Description: Personalized Medicine in the field of Transfusion Medicine
has impacted immunohematology testing, specifically RBC genotyping. Extended
matching of blood group antigens has shown utility in reducing alloimmunization
in transfusion recipients with sickle cell disease. However, Rh alloimmunization in
this population continues to occur and can cause significant challenges to finding
compatible blood. Genetic variation in the RH locus is very high in individuals of
African descent and recent evidence shows that this genetic variation is the
cause of a significant proportion of alloimmunizations among these patients. It is
important for BB and TS staff are aware of the availability and utility of RH
genotyping, as well as complex terminology of RHCE variants, as matching of
donor and patient of African descent based on serologic testing alone often
cannot detect the presence of variant antigens. This program will review the
genetic variation of the Rh blood group system and summarize RBC genotyping
of blood donors and patients. The session will use case studies to illustrate
scenarios where patients with variant Rh antigens, including those with
antibodies to high prevalence antigens hrS or hrB, can be more closely matched
with donors through the use of RH genotyping. The speakers will present the
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 61
status of their programs to offer most compatible blood to patients with variant Rh
antigens and alloantibodies.
(9330-TC-CT) AABB/NMDP Joint Program: Global Perspectives on Quality and
Biovigilance in Hematopoietic Cell Transplantation
Director/Moderator: John Miller, MD, PhD
Speaker: Bette Braem, MSSW, CMQ/OE (ASQ); John Miller, MD, PhD
Intended Audience: Physicians, Scientists, Technologists, Nurses,
Managers/Supervisors, CEOs/CFOs
Teaching level: Intermediate
Objectives:



Examine the context and array of quality-related events associated with
donor, patient and product safety in HCT manufacturing processes.
Understand global biovigilance efforts for adverse event reporting for HCT
donors and patients, including reporting requirements domestically and
internationally.
Describe the incidence of adverse events in HCT donors and how they
may vary in unrelated donors of PBSC and marrow and in related donors.
Event Description: Hematopoietic cell transplantation (HCT) provides life-saving
cures for an increasing number of patients world-wide with a variety of malignant
and non-malignant blood disorders. HCT is truly a global endeavor as
approximately one half of all transplants involve a donor and patient in different
countries. Accordingly, approaches to HCT quality and biovigilance need to be
developed domestically and be congruent with and support international efforts.
This session will look at efforts by NMDP to develop quality systems for marrow,
PBSC and cord blood units and their international labelling and distribution.
Protecting donor and patient safety are paramount in HCT, so robust biovigilance
systems need to be in place to monitor a full range of quality-related incidents,
including donor and patient adverse events, and to monitor product safety issues
as well. This session will describe what we have learned about donor and patient
adverse events and how we share these findings as international professionals
so we can learn how to ensure and improve our safety efforts worldwide.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 62
(9331-QE) Ask the FDA & CMS/CLIA
Director/Moderator: M. Allene Carr-Greer, MT(ASCP)SBB
Moderator: Sharon Carayiannis, MT(ASCP)HP
Speaker: Martin Ruta, JD, PhD; Salim Haddad, MD; Richard McBride, MS,
MT(ASCP)SBB; Wendy Paul, MD; Peyton Hobson, PhD; Beth Rogerson,
MT(ASCP)SBB; Safa Karandish, BS, MT(ASCP); Teresita Mercado, MS;
Jaroslav Vostal, MD, PhD
Intended Audience: Physicians, Scientists, Technologists, Nurses,
Managers/Supervisors, CEOs/CFOs
Teaching level: Intermediate
Objectives:


Describe FDA blood and HCT/P policies, regulations and inspection
programs.
Describe Clinical Laboratory Improvement Amendments (CLIA) regulations
that are applicable to blood and cellular therapy programs.
Event Description: This event provides an opportunity for discussion of FDA
and CMS/CLIA policies, regulations, guidance documents and inspection
programs that are relevant to the oversight of blood and HCT/P programs.
Questions for the discussion are submitted in advance via the AABB website.
(030H) Scientific Oral Abstract Session: RBC Immunohematology: CD38
Interference with Serologic Testing and KEL Expression Effects
(030I) Scientific Oral Abstract Session: Transfusion-Transmitted Infectious
Diseases: Babesia, Chagas and Other Infectious Diseases
(030J) Scientific Oral Abstract Session: Patient Blood Management
(030K) Administrative Oral Abstract Session: Inventory Management, Storage and
Distribution
(030L) Administrative Oral Abstract Session: Quality Management
(030M) Administrative Oral Abstract Session: Effective Continuing Education In
Immunohematology: Response To Unmet Training Needs
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 63
TUESDAY, OCTOBER 25, 2016
8:30 a.m. - 10:00 a.m.
(9401-S) Karl Landsteiner Memorial Award and Lectureship
Director/Moderator: Jose Cancelas, MD, PhD
Speaker: Stuart Orkin, MD
Intended Audience: Physicians, Scientists, Technologists, Nurses
Teaching level: Intermediate to Advanced
Objectives:




The global impact of hemoglobin disorders and potential strategies for
more effective management and/or cure.
The relevance of the human fetal-to-adult hemoglobin switch for the
hemoglobin disorders.
New genetic approaches, genome-wide association studies (GWAS) and
gene editing, and their power for understanding human disease biology. 4.
Challenges and potential solutions, in bringing new knowledge and
genetic tools to innovate therapy for patients.
Challenges and potential solutions, in bringing new knowledge and
genetic tools to innovate therapy for patients.
Award Description: Initiated in 1954 to honor Karl Landsteiner, MD, whose
lifetime research laid the foundation for modern blood transfusion therapy, this
award recognizes a scientist whose original research resulted in an important
contribution to the body of scientific knowledge. The scientist who receives the
award shall have an international reputation in transfusion medicine or cellular
therapies. The title of Dr. Orkins presentation is Solving the human fetal-to-adult
hemoglobin switch.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 64
(9403-QE) Biorepositories 101: What You Need to Know About Establishing and
Maintaining a High Quality Resource
Director: Michele Sugrue, MS, MT(ASCP)SBB
Moderator: Naynesh Kamani, MD
Speaker: Adriana Brigatti, JD, MPH, LLM, CIP, CHRC; Jim Vaught, Ph.D.;
Elizabeth Wagner, MPH
Intended Audience: Physicians, Scientists, Technologists,
Managers/Supervisors
Teaching level: Intermediate
Objectives:



Describe best practices in designing and maintaining a biorepository.
Review federal regulatory and institutional requirements as they apply to
the establishment of biorepositories.
Discuss ethical and legal considerations in the collection and use of
biorepository materials.
Event Description: In a special issue of Time magazine in 2009, biobanking
was featured as one of "10 ideas changing the world right now". Blood banks
serve as the quintessential examples of biorepositories in that they are facilities
for the collection, preservation, processing, storage and supply of biological
material and associated data, which follows standardized operating procedures
and supports clinical care and scientific investigation. Today, biorepositories are
becoming important sources for cutting edge clinical care studies and research
tools for studying disease and therapies. Biorepositories may include a wide
range of contents from genomic specimens used in precision medicine to
parathyroid tissue, corneal grafts, and bone material to name a few. Within this
session, faculty will describe best practices to ensure high quality sample and
data collection and storage. In addition, presenters will review the federal
regulatory requirements applicable to biorepositories as defined by FDA, DHHS
and HIPPA. Furthermore, ethical and legal issues affecting relationships between
donors and patients or researchers including the concept of donation, proper
informed consent, and protection of personal data will be discussed.
(9405-LMT) The Evolving Role of the Medical Function in the 21st Century Blood
Center — the Florida/OneBlood Experience
Director: Rita Reik, MD
Moderator: Richard Gammon, MD
Speaker: Rita Reik, MD; Richard Gammon, MD; Tisha Foster, MD; Harold
Alvarez, MD; Buff Mair, MD; Marsha Bertholf, MD
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 65
Intended Audience: Physicians, Scientists, Technologists, Nurses,
Managers/Supervisors, CEOs/CFOs
Teaching level: Intermediate to Advanced
Objectives:



Outline the process by which physician Medical Directors from four large
independent community blood centers, adapted and contributed to a
successful merger and integration, using a team approach coupled with
measurable goals, policies and bylaws.
Identify novel sources of revenue for the 21st century blood center that
may result from transitioning away from a traditional "value-added
services" approach to a billable fee-for-service model for the medical
team.
Describe how a large blood center merger creates a platform for scaled-up
data collection that enhances intramural research, as well as
collaborations with public health authorities and innovators in the blood
banking world resulting in improved safety and efficacy of transfusions.
Event Description: This session will explore the evolution of the blood center
physician's role that resulted as legacy system Medical Directors adapted to a
changing healthcare landscape of blood center mergers and shifting revenue
streams. The discussion will include individual physician's perceptions, and
experiences, and its scope will cover the areas of cellular therapies, therapeutic
apheresis, centralized compatibility testing, blood wellness and anemia clinics,
patient blood management models as well as traditional blood collection
activities. In addition, there will be a discussion of the impact of merging several
large donor databases on creating expanded research capabilities and
opportunities.
(9406-LMT) Coding and Reimbursement
Director/Moderator: Theresa Wiegmann, JD
Check back for faculty and a detailed description.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 66
8:30 a.m. - 12:00 p.m.
(9402-TC) Modern Day Immunohematology: The Power of Serology with DNA
Testing for Antibody Investigation
Director: Christine Lomas-Francis, MSc, FIBMS
Moderator: Mary Kowalski, MT(ASCP)SBB
Speaker: Sandra Nance, MS, MT(ASCP)SBB; Craig Tauscher, MT(ASCP),SBB,
MEd; E. Ann Steiner, MT(ASCP)SBB; Randall Velliquette; Sunitha Vege, MS;
Anna Burgos; Hallie Lee Stroka, MT(ASCP)SBB ; Rebecca Bullock; Regina
Leger, MSQA, MT(ASCP)SBB, CMQ/OE(ASQ)
Intended Audience: Physicians, Scientists, Technologists,
Managers/Supervisors
Teaching level: Intermediate to Advanced
Objectives:



Learn through group discussions how peers approach and solve antibody
identification problems.
Discover how the combined use of serology and DNA testing methods can
be used to solve difficult cases and why results of serology and DNA
testing might sometimes differ.
Explain the use of enzymes or chemicals and advanced serological
techniques as tools and discuss the importance of multiple methods for
antibody identification.
Event Description: Join peers for stimulating discussions and have fun solving
immunohematology problem cases with colleagues from near and far! Using a
round-table discussion format, this program will present basic to complex
immunohematology case studies led by a moderator and round-table team leads.
Utilizing small group discussions, participants will be given the opportunity to test
their interpretive skills to solve cases and expand their immunohematology
problem solving skills. Basic case studies incorporating routine serological
methods with an introduction to DNA-based testing methods will start off the
program with an evolution to complex cases incorporating more advanced
serological techniques and DNA-based testing assays.
(9404-QE) Teaching Problem Solving and Analytical Decision Making Skills
Director: Karen Byrne, MDE, MT(ASCP)SBB
Moderator: J. Wade Atkins, CQA(ASQ), MS, MT(ASCP)SBB
Speaker: Marilyn Moulds, BA, MT(ASCP)SBB; Yeon Mi Kim; Kate Hernandez,
MT(ASCP)SBB
Intended Audience: Physicians, Technologists, Managers/Supervisors
Teaching level: Basic to Intermediate
Objectives:
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 67



Clarify definition of problem solving and analytical decision skills.
Determine when skills are needed and who needs to have them.
Outline a process to follow when problem solving and analytical decision
skills are needed.
Critique several cases that demonstrate outcomes of using problem
solving and analytical decision making skills.
Event Description: One expected skill of anyone in working in transfusion
medicine is problem solving and analytical decision making. The individual
should be capable to implement and delegate decisions regarding laboratory
operation and exercise independent judgment in problem solving. This is a skill
not only for those in training programs but for all who work in transfusion
medicine. How does one teach this skill?? How does one demonstrate
competency? This workshop will introduce a method to help develop this skill.
Cases will be presented and a process will be discussed as to how to define the
problem, generate alternatives, evaluate and select alternatives, implement
solution, and determine its effectiveness.
10:30 a.m. - 12:00 p.m.
(9407-S) Platelets, Hemostasis, Infection and Sepsis
Director/Moderator: Olivier Garraud, MD, PhD
Speaker: Olivier Garraud, MD, PhD; Matthew Rondina, MD
Intended Audience: Physicians, Scientists, Technologists, Nurses, Perfusionists
Teaching level: Intermediate to Advanced
Objectives:



To understand the role of platelets as sentinels of invading bacterial and
viral pathogens, along to their function of sensors of vascular endothelium
aJri*on.
To demonstrate how platelet bacterial interactions, contribute to a
prothrombotic milieu, and also to discuss the main consequences of (viral)
infection on platelets and infection induced-thrombocytopenia.
To review emerging data on platelets as immune effector cells during-more particularly--bacterial infection.
Event Description: Although nucleate, platelets are key sentinels residing within
the vascular space and mediate key aspects of surveillance, host defenses, and
containment to invading bacterial (and viral) pathogens. Activation of platelets by
infectious pathogens and toxins induces not only hemostastic responses bay
also immune and inflammatory pathways. Dysregulated platelet activation during
human infectious syndromes contributes either to pro-thrombotic outcomes, or to
severe hemorrhagic syndromes.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 68
(9408-S-CT) What is the Blood Bank's Role in T-cell Immunotherapeutics?
Director/Moderator: Philip Norris, MD
Speaker: David McKenna, MD; Bruce Levine, PhD
Intended Audience: Physicians, Scientists, Technologists, Nurses
Teaching level: Intermediate to Advanced
Objectives:



Understand where the field of T cell therapy is and will be headed clinically
and scientifically.
Learn who is producing T cell therapeutics and why (economic, technical,
and regulatory factors).
Forecast where blood banks will contribute to T cell therapy.
Event Description: T cell therapies are being scaled-up and translated to clinical
treatment protocols at an accelerating pace. Potential indications for T cell-based
treatment include chimeric antigen receptor (CAR) T cells or expanded tumorinfiltrating lymphocytes for cancer treatment, regulatory T cells for GVHD and
other applications, and anti-viral T cells as prophylaxis or treatment after bone
marrow transplant. How blood banks will be involved in producing the raw
materials or finished products for each of these therapies is unclear. This session
will explore how T cell-based therapies are currently prepared for clinical trials,
as well as how the blood bank interfaces with industrial producers of T cell
therapies. Issues such as technical hurdles in scale-up of production and
regulatory requirements will be discussed.
(9409-TC-PBM) Evidence-Based Medicine in the Perioperative Arena
Director/Moderator: Mary Berg, MD
Speaker: Mary Berg, MD; Camille van Buskirk, MD; Scott Brown, MS, CCP, LP
Intended Audience: Physicians, Nurses, Managers/Supervisors, Perfusionists
Teaching level: Basic to Intermediate
Objectives:



Discuss the risks and benefits of using cell salvage in cases of malignancy
or infection.
Describe the contents and potential uses of autologous platelet gel.
Describe the contents and potential uses of autologous bone marrow
aspirate.
Event Description: New modalities in use in perioperative areas have few
studies to support their use. Traditional cell salvage, which has been available for
many years, still is not routinely used for obstetric cases or cases of malignancy
or infection. This session will review published studies to discuss whether or not
they support the use of bone marrow aspirate and platelet get. Similarly, studies
regarding the use of cell salvage in controversial situations will also be reviewed.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 69
(9410-TC) Back to Basics: Do We Really Know it all When it Comes to Platelet
Manufacturing and its Impact on Detection and Prevention of Bacterial
Contamination of Blood Components
Director/Moderator: Sandra Ramirez-Arcos, PhD, MSc
Speaker: Anne Eder, MD, PhD; Sandra Ramirez-Arcos, PhD, MSc; Dirk De
Korte, PhD
Intended Audience: Physicians, Scientists, Technologists
Teaching level: Basic to Intermediate
Objectives:



Describe how platelet manufacturing processes affect bacterial distribution
into different blood components and their detection in the final products.
Discuss the impact of bacteria growth dynamics and biofilm formation
during platelet storage on bacterial detection methods and pathogen
reduction technologies.
Propose integrated, innovative activities to address the residual risk of
transfusing bacterially-contaminated blood products.
Event Description: Despite the implementation of several mitigation measures,
blood product contamination with bacteria still constitutes the highest posttransfusion infectious risk. Current efforts are focused on changing sampling
algorithms, improving screening methods or implementing pathogen reduction
technologies. However, very few studies are focused on understanding how
blood component collection, manufacturing, and storage influence bacteria
growth and physiology and the potential clinical impact of these factors.
Speakers in this session will review the current knowledge on platelet
manufacturing and its impact on bacteria growth, detection and prevention in the
final products, and stimulate a discussion on novel approaches to enhance blood
product safety.
(9411-TC) Comprehensive Perinatal Management Programs
Director/Moderator: Debra Lane, MD, FRCPC
Speaker: Debra Lane, MD, FRCPC; Gwen Clarke, BSc, MD
Intended Audience: Physicians, Technologists, Nurses
Teaching level: Intermediate
Objectives:



Review perinatal laboratory investigations.
Describe the multi-provincial efforts in Canada to standardize perinatal
laboratory investigations.
Discuss the cost and benefits of implementing testing of maternal plasma
for fetal DNA typing in managing pregnancies.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 70
Event Description: Over the last ten years, there have been many efforts to
standardize laboratory policies and practices form the management of perinatal
care in Canada. Recently the use of maternal plasma for fetal DNA testing has
been added to the platform to provide enhanced perinatal care. The challenges
of providing perinatal care where patients are distant from care will be discussed.
The costs and benefits adding testing of maternal plasma for fetal DNA will be
discussed. Comprehensive perinatal programs in Europe will be reviewed.
(9412-QE) Training Programs as the Foundation to the Roadmap to Accreditation
Director: Christine Bales, BS, MT(ASCP), I (ASCP), CQA(ASQ)
Moderator: Diane De Coning, B Sc
Speaker: Christine Bales, BS, MT(ASCP), I (ASCP), CQA(ASQ); Diane Coning,
B Sc
Intended Audience: Physicians, Technologists, Nurses, Managers/Supervisors,
CEOs/CFOs
Teaching level: Intermediate to Advanced
Objectives:



The audience will learn the importance of developing multidiscipline
training programs that support AfSBT/AABB accreditation.
To demonstrate how training programs identify gaps that may not have
been identified in an accreditation readiness baseline assessment.
The audience will understand that a cohesive and planned training
program is the foundation of the Roadmap to Accreditation.
Event Description: The AABB International Technical Assistance (TA) Team
introduces their approach to achieving Africa Society for Blood Transfusion
(AfSBT) and AABB accreditation in TA supported countries in Sub-Saharan
Africa through Quality and Technical/Operational training programs. These
training programs are the foundation of the Roadmap to Accreditation and are
based on adult learning principles. The TA team of experts in various disciplines
(Donor Management, Laboratory, Quality Management and Operations) provide
brief summaries of the training programs and the expected results achieved to
support accreditation readiness. Training programs subjects include:
Infrastructure (Sustainability), Clinical Interface, Quality Management Systems,
Donor Recruitment, Blood Collection, Laboratory Practices (testing and
component production), Information Technology, and Balanced Scorecard. After
the discussion of the training programs, an update on the progress and
accomplishments of the countries supported by AABB International Technical
Assistance is presented and followed by a Q & A session.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 71
(9413-LMT) This Isn't Your Mother's Blood Bank Any More! New Collaborative
Realities between Hospitals and Blood Suppliers: It's the People, Processes, and
Products That Improve Patient Outcomes and Customer Service
Director: Barbara Swanson, MEd, MT(ASCP), CQA(ASQ)
Moderator: Houston "Buddy" Nguyen, BSCLS, MT(ASCP), BIT
Speaker: Barbara Swanson, MEd, MT(ASCP), CQA(ASQ); Houston "Buddy"
Nguyen, BSCLS, MT(ASCP), BIT; Allison Kelly, MLS(ASCP)SBB
Intended Audience: Physicians, Technologists, Nurses, Managers/Supervisors
Teaching level: Intermediate
Objectives:



Understand how the blood supplier partnered with the hospitals and
Transfusion Services for improving efficiencies in the Transfusion Service.
Describe how implementing changes to long held Transfusion Service
practices has allowed the Transfusion Service to significantly decrease
red cell inventory, improve turn-around-time and decrease unnecessary
crossmatching.
Explain how a blood supplier can successfully assist in the implementation
of a patient blood management program.
Event Description: Description: The face of the 2016 blood bank from donor to
patient continues to change with unparalleled speed. The blood supplier, the
Transfusion Service and the hospital's medical and administrative teams are
partnering to improve patient outcomes and customer service. In this program,
the participant will hear from key constituents who will share their challenges and
successes working to change old practices, implement new processes and
assimilate new evidence-based recommendations and information about blood
products
(9414-LMT) Playing Nice in the Sandbox: How to Get Along with Others and How
to Help Others Get Along with You
Director: Judy Brazell, MA, MT(ASCP)SBB, CQA(ASQ), LPCI
Moderator: Ruth Biehl, MS, MBA, MLS(ASCP)CM, CMQ/OE(ASQ), CQE(ASQ)
Speaker: Judy Brazell, MA, MT(ASCP)SBB, CQA(ASQ), LPCI; Mark Bolte, PsyD
Intended Audience: Physicians, Technologists, Nurses, Managers/Supervisors,
CEOs/CFOs
Teaching level: Basic to Intermediate
Objectives:


Increase Self-awareness by understanding your needs and interpersonal
style.
Know your "conflict management style" and apply this to more effective
conflict resolution.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 72

Develop strategies for dealing with "difficult" people and improve your
interpersonal effectiveness.
Event Description: The quality and effectiveness of one's working relationships
are essential to job satisfaction, retention, and productivity. This interactive
workshop will aid in how to better understand your interpersonal style and needs,
and how to interact and influence others with greater effectiveness. Special focus
will be on conflict management strategies, self-awareness as a leader, and
dealing with "difficult" people. Join an expert in the industry and a clinical
psychologist to explore the unique ways we can all work together more
effectively.
2:00 p.m. - 3:30 p.m.
(9415-TC) Blood Group Systems Update: Everything RH
Director/Moderator: Greg Halverson, MT(ASCP)SBB, DLM
Speaker: Connie Westhoff, PHD, SBB; France Pirenne, MD, PhD; Thierry
Peyrard, PhD, PharmD, EurClinChem
Intended Audience: Scientists, Technologists, Managers/Supervisors
Teaching level: Intermediate to Advanced
Objectives:



To understand the latest changes and additions to the Rh Blood Group
System.
Learn how to manage D variant and D weak patients regarding the use of
Rh D negative blood and Rh Immune Globulin.
Be able to recognize Rh system variants and when there must be closer
matching for patients that have variant antigens.
Event Description: This session is meant to discuss new antigens and alleles in
the Rh Blood Group System and learn how molecular genotyping has an
important role in matching blood for chronically transfused patients such as those
with Sickle cell disease and Thalassemia. Three speakers will address specific
areas of RhD weak and RhD variants and the numerous variants in the RhCE
allele. The primary focus will be to provide information regarding donor matches
for patients with variant blood group antigens who are in danger of producing
antibodies to high frequency antigens.
(9416-TC-CT) Emergency INDs-How, When to Submit and What We Do and Do Not
Learn from Treatment by Exception
Director/Moderator: Jed Gorlin, M.D., M.B.A.
Speaker: Victor Baum; Jed Gorlin, M.D., M.B.A.; Jerome L. Gottschall, MD;
Richard Weiskopf, MD; Laura Cooling, MD, MS
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 73
Intended Audience: Physicians, Scientists, Technologists, Nurses, Perfusionists
Teaching level: Intermediate to Advanced
Objectives:



Describe circumstances where use of novel unlicensed products may be
required, including the treatment of Jehovahs Witness patients.
Describe the FDA approval process for an emergency IND.
Describe limitations to the therapeutic conclusions that can be drawn from
uncontrolled usage of unlicensed products.
Event Description: Several Presenters will share clinical cases of obtaining an e-IND
(formerly compassionate use protocol). Cases involve use of hemoglobin based oxygen
carriers for patients failing or refusing conventional transfusion therapy. The process for
obtaining approval (both from manufacturer and the FDA) will be shared. While
publications of such cases typically report only positive outcomes (publication bias), can
we learn any lessons from case series.
(9417-TC) Transfusion Thresholds and Ethics of Transfusion in the Beating Heart
Organ Donor Population
Director/Moderator: Emily Coberly, MD
Speaker: Eric Gehrie, MD; David Chooljian, MD, JD
Intended Audience: Physicians, Scientists, Technologists, Nurses,
Managers/Supervisors, Perfusionists
Teaching level: Intermediate
Objectives:



Assess the latest evidence for transfusion thresholds, and determine how
this evidence might apply to the beating heart organ donor population.
Evaluate current transfusion practices in beating heart organ donors.
Consider the ethical implications of transfusion in beating heart organ
donors.
Event Description: Beating heart organ donors (BHODs) are a common source
of transplant organs in Western countries, but evidence regarding optimal
transfusion practice in this population is currently lacking. In this session, we will
review the current evidence for transfusion thresholds as it may apply to BHODs
and will evaluate current transfusion practices in BHODs, including a focused
discussion of the ethical implications of transfusion in this population.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 74
(9418-TC-PBM) Transfusion Practice: Management of the Obstetrical Patient
Director/Moderator: Theresa Nester, MD
Speaker: Kerry O'Brien, MD; Kathleen Puca, MD; Evelyn Lockhart, MD
Intended Audience: Physicians, Technologists, Nurses, Managers/Supervisors
Teaching level: Intermediate
Objectives:



Describe the current recommendations for blood management in obstetric
hemorrhage, emphasizing recent data.
Review the current recommendations for the use of cell salvage during an
obstetric hemorrhage.
Discuss recent data on adjuvant pharmacotherapy use in obstetric hemorrhage,
including fibrinogen concentrates and tranexamic acid.
Event Description: Using case-based scenarios, session attendees will be polled to
determine their current understanding of, and practice recommendations for, specific
clinical scenarios involving the pregnant patient. The emphasis of the session will be
to present updated recommendations and new findings since the AABB 2014 annual
meeting. Topics will include the role of cell salvage and antifibrinolytics in obstetric
hemorrhage. Data on laboratory predictors of severe post-partum hemorrhage and
fibrinogen repletion during obstetric hemorrhage will also be reviewed.
(9419-TC) Biosimilars and Biobetters - Focus on biosimilar G-CSF
Director/Moderator: Halvard Bonig, MA, MD
Speaker: Halvard Bonig, MA, MD; Henry Grabowski, Ph.D.; Arnon Nagler, MD
Intended Audience: Physicians, Scientists, Technologists, Nurses,
Managers/Supervisors, CEOs/CFOs
Teaching level: Intermediate
Objectives:



Understand and apply the concept of "biological similarity" as applied to
biosimilars.
Identify risks and benefits of biosimilars - medical as well as economical.
Make informed decisions about the evidence of (clinical) similarity of
biosimilar G-CSF.
Event Description: Session will explore how biosimilars are developed and
approved, how similarity is demonstrated, what are the potential economical
benefits of biosimilars, but also what are the risks and why the potential benefits
might not play out. Finally, the cumulative evidence of clinical similary (or
dissimilarity) of biosimilar G-CSF is explored.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 75
(9420-QE) Competency Assessment - Is it Fair?
Director: Betsy Jett, MT(ASCP), CQA, CMQ/OE (ASQ)
Moderator: Donna Strauss, MS
Speaker: Sarai Paradiso; Kim Mielenz, BS,; Kathleen Crowley, MT(ASCP)SBB
Intended Audience: Technologists, Nurses, Managers/Supervisors
Teaching level: Intermediate
Objectives:



Outline the value and benefits of performing proper competency
assessments of technical employees.
Provide guidance on developing appropriate competency assessment
tools.
Discuss the challenges in performing an objective competency
assessment on coworkers.
Event Description: Performing Competency Assessment of Technical staff in
the Blood Industry is not only a regulatory requirement but can be of great value
when done properly. Technical staff in a Blood Center not only includes Medical
Technologists, but also Collections and Manufacturing staff. Performing periodic
competency assessments in a regulated environment can be challenging.
Developing tools that are compliant with regulatory standards and robust enough
to properly measure competency is not always as simple as it seems. Selecting
responsible assessors and ensuring that they themselves are competent in both
technical procedures and observational and interpersonal skills is also extremely
important. Performing an objective, unbiased assessment of coworkers can be
difficult for many staff. This session will describe the elements that should be
included in competency assessment and identify the risks of performing a biased
assessment. In the end, Competency Assessment is only as good as the tools
and the assessor.
(9421-QE-CT) Have You Counted Sources of Variability For Your Stem Cell
Characterization Testing?
Director: Ljiljana Vasovic, MD
Moderator: Olive Sturtevant, MHP, MT(ASCP)SBB, SLS, CQA(ASQ)
Speaker: Vasiliki Kalodimou, PhD; Laura Connelly-Smith, MD; Michael
Linenberger, MD; Olive Sturtevant, MHP, MT(ASCP)SBB, SLS, CQA(ASQ)
Intended Audience: Physicians, Scientists, Technologists, Nurses,
Managers/Supervisors, CEOs/CFOs
Teaching level: Basic to Intermediate
Objectives:


Standardizing Post Thaw CTP Recovery, Viability and Potency.
Reproducibility, Accuracy and Comparability of CTP Biological Assays.
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 76

Improving Your 95% Confidence Interval.
Event Description: Laboratory test results guide for your patient Cellular
Therapy Product (CTP) treatment strategies. Sampling strategy: When and
where? Not all TNC, MNC, CD34, Viability, CFU tests are created equal. Preanalytical, analytical and post-analytical errors in CTP quality testing. How many
assays do you need to be confident that reported result accurately describe your
CTP? How do we measure Stem Cell Potency globally?
(9422-LMT) Ethical Dilemmas in Transfusion Practices in Developing Countries
Director/Moderator: Quentin Eichbaum, MD, PhD, MPH, MFA, MMHC,
BSc(Med)(Hons), BA(Hons)
Speaker: Silvano Wendel, MD,PhD; Hua Shan, MD, PhD; Ravi Reddy; Quentin
Eichbaum, MD, PhD, MPH, MFA, MMHC, BSc(Med)(Hons), BA(Hons)
Intended Audience: Physicians, Scientists, Technologists, Nurses,
Managers/Supervisors, CEOs/CFOs, Perfusionists
Teaching level: Intermediate to Advanced
Objectives:



To present an overview of global health ethics as it pertains to health care
delivery related to transfusion practice in developing countries.
To present cases of ethical dilemmas arising from transfusion practices in
developing countries.
To engage the audience in exploring solutions to these ethical dilemmas.
Event Description: This session will first present an overview of global health
ethics as it pertains to transfusion practices in developing countries. We will
present specific CASES of ethical dilemmas in transfusion practices in various
resource-constrained settings of developing countries. We will engage the
audience in exploring solutions to these dilemmas, and highlight similarities and
differences in practices between developed and developing countries.
(040A) Scientific Oral Abstract Session: RBC Immunohematology: Studies of
Alloimmunization Against RHD and Other Blood Groups
(040B) Scientific Oral Abstract Session: Platelet and Leukocyte Biology
(040C) Scientific Oral Abstract Session: Components and Component Processing
II
(040D) Scientific Oral Abstract Session: Donor and Therapeutic Apheresis
2016 AABB Annual Meeting Preliminary Program | www.aabb.org/annualmeeting | page 77